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1.1 Glycobiology 
 
Glycobiology is an interdisciplinary science, crossing the fields of chemistry, biology and 
medicine studying all the aspects of the structure, biosynthesis and functions of glycans 
widely distributed in nature. A very broad spectrum of functions have been assigned to 
glycans, besides the well-known, energetic and structural role they have.1 Nowadays is 
well known that carbohydrates, together with nucleotides and amino acids, are one of the 
most important class of biomolecules in nature. In fact, they not only have an important 
structural and protecting role and are the main energy reserves of cells, but they are also 
involved in many important cellular processes thanks to specific interactions with 
different chemical or biological species as, for example, viruses, bacteria, proteins, nucleic 
acids, hormones and acting as mediators for cell-cells communication2 (fig. 1.1). In most of 
such processes a carbohydrate ligand usually binds to a protein receptor.3,4 Therefore there 
is an increasing interest in the synthesis of new neoglycoconjugates or high affinity mimics 
of native saccharides which could interfere in these recognition processes; such 
compounds have potential therapeutic value in the treatment of infections and of a wide 
range of human tumours. The study and understanding of protein–carbohydrate 
interactions is, for these reasons, really important. 
 
 
Figure 1.1 Representation of some of the possible interactions between membrane glycans and protein 
receptors of different biological entities.5 
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A complete understanding of all the roles that carbohydrates have in the so many 
physiological and pathological events of the cell is a quite difficult challenge. One reason 
lies in the structural complexity of oligosaccharides. In fact, while the other two classes of 
biopolymer, nucleic acids and proteins, have a linear arrangement of repeating units, 
carbohydrate building blocks have multiple points of attachment, leading to highly 
branched and stereochemically differentiated structures6 (fig. 1.2). This structural 
complexity is further increased by post–synthetic modifications: hydroxyl groups can be 
sulphated, phosphorylated, acetylated, oxidized or replaced with other functional groups, 
especially those containing nitrogen in order to tune distinct biological activities.7  
 
 
Figure 1.2 Building blocks of oligosaccarides (a), proteins (b) and nucleic acids (c), with evidenced in bold 
the groups potentially involved in oligomerization processes. 
 
This incredibly high structural diversity which can be generated by these oligosaccharides, 
called Sugar Code,8 stores detailed biochemical information which can be translated by 
suitable sugar binding proteins. 
A second difficulty in studying carbohydrate-protein interactions is that binding affinities 
are weak, with dissociation constants in the milli-micromolar range;3 however, the 
efficiency and selectivity of the in vivo control of events mediated by protein–carbohydrate 
binding requires significantly greater affinity. Nature overcomes this limitation by 
combining multiple simultaneous interactions between two or more carbohydrates of the 
glycoproteins organised in domains on the cell surface and a corresponding multimeric 
protein (fig. 1.1). These multivalent interactions have several mechanistic and functional 
advantages over their monovalent counterparts, the most relevant one probably being the 
ability to increase the specificity of binding. It is not surprising therefore that nature uses 
carbohydrates to mediate and encode the information for many biochemical processes, 
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exploiting the high specificity in the ligand-receptor interactions. Immunological 
response,9,10,11 tumour metastasis,12 fertilization13 and inflammation14 are just some 
examples of the processes in which carbohydrates take part. Besides they act as mediators 
in diverse cellular activities, such as recognition, growth and apoptosis.15,16 
 
 
1.2 Carbohydrate binding proteins: Lectins 
 
The initial contact between two cells or a cell and a pathogenic agent, often starts with a 
carbohydrate-protein recognition process. The outer surface of cells shows a complex set 
of carbohydrates, called glycocalyx, usually belonging to oligo-, poly-saccharides, 
glycolipids and glycoproteins. The proteins which non-covalently interact with 
carbohydrates are generally called carbohydrate binding proteins (CBP). In nature, there 
are several families of these kind of proteins, such as carbohydrate-specific enzymes and 
anti-carbohydrate antibodies. A very important class of CBP that has recently raised the 
interest are lectins:17,18,19 proteins able to bind carbohydrates but without any catalytic or 
immunogenic activity. Furthermore lectins appear as more and more attractive targets for 
new diagnostic and therapeutic strategies, since it was demonstrated, in the second half of 
the last century, their involvement in physiological and pathological phenomena, from cell 
differentiation to cancer.20 The study of lectins and their role in cell recognition processes, 
as well as the application of these proteins to the study of carbohydrates in solution and 
on cell surfaces, are giving important contributions to the advancement of glycobiology.21 
Lectins are divided, according to their origin, in microbial, plant or animal18 lectins. 
Initially they were classified, into five groups, depending on the specificity to the 
monosaccharide for which they exhibit the highest affinity:  
• D-mannose,  
• D-galactose/N-acetyl-D-galactosamine,  
• N-acetyl-D-glucosamine,  
• L-fucose,  
• N-acetylneuraminic acid. 
Relevant for the biological activities of lectins is the fact that notwithstanding the 
numerous monosaccharides found in nature, only those listed above are typical 
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constituents of surfaces of eukaryotic cells. The classification of lectins according to their 
monosaccharide specificity, however, masks the fact that they often exhibit an exquisite 
specificity for di-, tri-, and tetrasaccharides (with association constants up to 1000-fold 
higher as compared with the monosaccharide) and that certain lectins interact only with 
oligosaccharides. Moreover, lectins of the same specificity group may differ markedly in 
their affinities for different oligosaccharides. However, also thanks to the high-resolution 
X-ray crystallography of lectins and their complex with carbohydrates it was possible to 
identify the carbohydrate recognition domain (CRD): therefore, the more accepted current 
classification of lectins is based on the homology of their CRD (Table 1.1).  
 
Lectin Family Cation 
dependency 
Carbohydrate specificity 
C-type Yes variable (Man, Gal, Fuc) 
I-type No variable (Man, GlcNAc, α(2,3)/α(2,6)-Sia) 
S-type (Galectins) No β-Gal 
F-type Yes Fuc 
P-type Variable Man-6-P 
R-type No β-Gal 
Table 1.1 Current categories for classification of various animal lectins. 
 
Other families of animal lectins, which include pentraxines (pentameric subunit 
arrangement), ganglioside binding proteins, sulfoglucoronosyl lipid-binding proteins and 
others, resist to this classification because of differences in their CRD that do not allow to 
find sequence homologies or evolutionary relation. 
A very important class of animal lectins are galectins. They recognize glycoconjugates 
presenting a terminal β-galactose residue and show a conserved amino acid sequence 
consisting of approximately 130 residues for the carbohydrate binding domain.22 Galectins 
are mainly located in the nucleus and cytoplasm, although they can be found also at cell 
surface or within the extracellular matrix where they can interact with glycosylated 
compounds.23,24 
Considering their importance in a number of biological processes, it is not surprising that 
galectins have recently been under intense investigations. They take part in the cell-cell 
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communication, adhesion and cell migration processes. They also have a role in embryonic 
development, differentiation and RNA splicing.25 Moreover, galectins are involved in 
inflammatory processes (for example Galectin-1 acts as anti-inflammatory agent,26 
oppositely to Galectin-3 which instead shows pro-inflammatory activity27), apoptosis (for 
example Galectin-1 induces apoptosis of activated human T cells and human T leukemia 
cell lines,28 while Galectin-3 contributes in preventing this mechanism29), tumor growth 
and metastasis.30, 31, 32 Currently, fifteen members of this family have been identified in 
mammals.33 Because of the lack of human counterparts of Galectins -5, -6, -11, -14 and -15, 
there are only 10 types of human Galectins. However, based on their structure, Galectins 
can be also divided into three subgroups: proto-type, tandem-repeat-type and chimera-
type (fig. 1.3). 
 
 
Figure 1.3 The schematic representation of the three different structures of human Galectins 
 
Proto-type Galectins (-1, -2, -5, -7, -10, -11, -13, -14 and -15) contain one carbohydrate 
recognition domain (about 15 kDa) and they can be in the form of monomers or 
homodimers; tandem-repeat-type Galectins (-4, -6, -8, -9 and -12) present two distinct 
CRDs in a single peptide chain; chimera-type, whose only member is Galectin-3 (about 30 
kDa), is constituted by one CRD with a non lectin part directly connected to it, which is 
responsible for the oligomerization,34 usually pentamerization. Due to the simultaneous 
presence of several CRDs, when binding to multivalent glycosylated substrates Galectins 
can form lattices and undergo agglutination. 
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1.3 Multivalency 
 
Even if Galectins bind saccarides with high specificity, a single carbohydrate-protein 
interaction shows rather weak binding, with dissociation constants in the milli-micromolar 
range. In order to enhance the binding affinity and overcome this limitation, nature 
exploits a powerful tool, the multivalency,35 that in case of proteins binding to 
carbohydrates is also named “glycoside cluster effect”.3,36 It consists in the ability of a 
multimeric receptor to interact with a multivalent ligand via several, simultaneous, 
noncovalent recognition events (fig. 1.4) giving rise to an overall free energy of binding 
(∆G°multi) that is higher than the simple sum of the free energy of the single monovalent 
interactions (∆G°mono). 
 
 
Figure 1.4 Example of monovalent vs multivalent complexes.37 
 
Multivalent interactions usually result in high specificity and thermodynamic and kinetic 
stability.  
Sometimes the concept of multivalency is associated with the one of cooperativity, that on 
the contrary is generally intended as the influence of the binding of one ligand on the 
receptor’s affinity toward further binding.38 However, as elegantly pointed out by 
Ercolani,39 cooperativity in multivalent systems is usually extremely scarce and rare. 
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Moreover, cooperativity can be easily and rigorously assessed by using Hill or Scatchard 
plots for the binding of monovalent ligands to a multivalent receptor, as in the binding of 
four O2 molecules to tetrameric haemoglobin. Much more difficult is to prove its existence 
when a multivalent ligand interacts with a multivalent receptor.  
Initially, when a multivalent receptor and a multivalent ligand start to bind to each other, 
the first possible interaction is obviously intermolecular, but then a competition between 
inter- and intra-molecular binding events can take place. If the former are predominant, 
intermolecular aggregates of variable stoichiometry are the result of the binding, 
otherwise, if the latter are preponderant, the formation of a 1:1 receptor-ligand multivalent 
complex will be obtained (fig. 1.5).  
 
∆G inter
+
multivalent complex
(n-2) ∆G intra
+
intermolecular aggregate
°
°
∆G inter°
∆G intra°
 
Figure 1.5 Intermolecular and intramolecular processes for the formation of a multivalent complex or of an 
intermolecular aggregate.37 
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In general, to describe multivalent binding, an approach based on the additivity of the free 
energies40 can be used. The standard binding free energy for multivalent binding ∆G°multi 
is 
∆G°multi = n∆G°mono + ∆G°interaction 
 
where ∆G°mono is the standard binding free energy of the corresponding monovalent 
interaction, n is the valency of the complex and ∆G°interaction is the balance between 
favourable and unfavourable effects of tethering. Multivalency is obviously observed 
when ∆G°interaction is favourable to binding (∆G°interaction < 0). 
A rather qualitative but often useful parameter, β, has been introduced by Whitesides et 
al.,35 as  
β = Kmulti/Kmono 
 
where Kmulti and Kmono are the association constants for the multivalent and monovalent 
complexes, respectively. The parameter β, named enhancement factor, has been often used 
in the literature to compare the efficiency of multivalent ligands having different topology 
and/or valency: molecules with high β values are efficient ligands/inhibitors. Sometimes, 
if the valency n of the complex is know, this enhancement factor can be normalised to n, 
giving rise to the parameter β/n. Similarly, another way to evaluate the presence of 
multivalent effect is based on relative potency (rp), been defined as  
 
rp = IC50mono/IC50multi 
 
where IC50 are values of the multivalent (IC50multi) and monovalent (IC50mono) inhibition. 
Also rp can be normalised to the valency n giving rise to rp/n, relative potency per ligating 
unit (sugar).  
More rigorous approaches have been proposed by Kitov and Bundle41 to quantitatively 
describe the multivalent binding process. They developed a model, adapting the one from 
Jenks,40 where the standard free energy of multivalent interaction, ∆G°avidity, is a function 
of three terms ∆G°inter, ∆G°intra (binding free energies for the first intermolecular and the 
second intramolecular process, respectively, fig. 1.5) and a statistical term ∆S°avidity, namely 
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avidity entropy, calculated on the basis of the topology of the complex and representing the 
probability of association and dissociation of individual arms. The avidity entropy can 
grow rapidly with the valency of the complex, always favouring binding of a multivalent 
ligand to a multimeric receptor. This explains why multivalency can overcome the loss of 
conformational entropy. By a nonlinear fitting of the measured binding energies for a 
series of multivalent ligands, ∆G°inter and ∆G°intra can be determined, thus allowing to 
design and maximise the avidity of multivalent ligands.  
 
 
1.4 Multivalent glycosylated ligands 
 
This discovery of functional lectin–carbohydrate interactions and the possibility to inhibit 
them by using small polyglycosylated molecules offer enormous potential to the design of 
new drugs which could interfere with several pathological events.  
In the last decade, Supramolecular Chemistry became more and more interested in 
applying the multivalency concept to the recognition of biological important molecules 
and to nanotechnology and for this reason molecular design became essential. In fact an 
appropriate spatial disposition of ligands is the prerequisite to obtain the perfect matching 
between the protein receptor site and ligand binding functionalities. 
Multivalent ligands (fig. 1.6) can be of different type, but usually they have some common 
features that consist of a main core, called scaffold, bearing several covalent connections, 
the linkers or spacers, and the peripheral ligating (binding) units.  
Any multivalent scaffold can in principle be used, from those having low valency such as 
benzene derivatives, monosaccharides, transition metal complexes, azamacrocycles, 
cyclodextrins or calixarenes to high valency ones such as dendrimers, polymers, peptoids, 
proteins, micelles, liposomes, and self-assembled monolayers (SAMs) on nanoparticles or 
plane surfaces.  
Once the core structure where to anchor the binding moieties is fixed, two fundamental 
parameters for the ligand design are the nature and lenght of the spacers. In fact, they can 
influence the type and strength of the resulting interaction with the multivalent 
receptor.35,42 
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Figure 1.6 Different topologies of multivalent ligands. a) 1-D linear arrangement, b) 2-D cyclic/macrocyclic; 
c) 3-D cavity containing scaffolds (cyclodextrins/calixarenes); d) polymers/peptoids; e) 
nanoparticles/dendrimers/liposomes; f) 2-D 
 
Since multivalency can be explained mainly through entropic effects a positive entropic 
factor, able to favour intramolecular binding, can be obtained through the use of spacers of 
proper length. Spacers that are too short cannot allow the simultaneous interaction of all 
the ligating units with the receptor sites, while spacers that are too long can lead to an 
useless loss of roto-translational degrees of freedom. In both cases intermolecular binding 
would result favoured instead of the multivalent complex formation.  
 
 
1.5 Calix[n]arenes 
 
Many polyglycosylated molecules have been prepared as multivalent ligands to study 
multivalent carbohydrate-protein interactions.43 Calixarenes,44,45 the cyclic oligomers 
obtained by the condensation of phenols and formaldehyde (fig. 1.7), are ideal scaffolds 
for the construction of multivalent glycosylated ligands with unique properties. In fact, the 
valency of the calix[n]arene scaffold can be properly varied (4 < n < 8) by choosing the 
desired dimensions of the macrocycle. The even-numbered macrocycles (n = 4, 6, 8), aside 
from being commercially available, are also easily obtained, even in kilogram scale, using 
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cheap reagents through well-consolidated synthetic procedures.22 The odd-numbered 
homologues (n = 5, 7, 9), although known in the literature, can be obtained through more 
demanding syntheses, especially in terms of separation protocols, and are only rarely 
used. Glycoclusters with a lower valency (2 and 3) can also be readily prepared by 
selectively functionalising especially calix[4]arenes. 
 
 
Figure 1.7 a) CH2-bridged calix[n]arenes or simply calix[n]arenes with notation of the number n of repeating 
-ArCH2- units and b) resorcarenes, also belonging to the family of the calixarenes; (c) a picture of a Greek 
vase (calyx krater), whose shape inspired the name of the molecule. 
 
An important peculiarity of calix[n]arenes is the dual possibility to keep them 
conformationally mobile to exploit an induced-fit binding, or, on the contrary, to finely 
lock them in a specific structure more preorganized for binding. Especially in the case of 
the calix[4]arene, for instance, while the tetramethoxy- (fig. 1.8, R = Me) and tetraethoxy 
derivatives (fig. 1.8, R = Et) are conformationally mobile, the introduction of groups larger 
than ethyl, via efficient stereoselective procedures, can lock the macrocycle into one of the 
four possible structures (fig. 1.8) named by Gutsche as cone, partial cone, 1,3-alternate and 
1,2-alternate,44 that are characterised by a remarkably different orientation of the phenolic 
units into the space. 
 
Figure 1.8 The four limiting conformations of calix[4]arenes, when R > Et. 
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In larger calix[n]arenes (n > 5), the conformational control becomes more difficult; the 
macrocycle is usually present as a mixture of conformers that possess similar energies and 
rapidly interconvert from one to another (conformationally mobile derivatives). Extensive 
bridging at the upper or lower rim is needed to fix these calix[n]arenes in one particular 
structure.44 
 
 
1.5.1 Glycocalixarenes 
 
Carbohydrates can be efficiently introduced on calixarenes, through a proper spacer, both 
at the phenolic oxygen atoms (lower rim, fig. 1.7) and/or at the para position (with respect 
to the OH group) on the aromatic nuclei (upper rim, fig. 1.7), giving rise to glycoclusters 
with quite different characteristics. Therefore, the considerable success met by calixarenes 
as scaffolds for the construction of multivalent ligands is due to a combination of different 
factors, such as the ease to modulate the valency, size, structure and topology of the 
binding group presentation together with their straightforward preparation and ease of 
functionalization. Currently, the chemistry of calixarenes is, in fact, well consolidated, and 
different and effective methods are known for the introduction of chains, both at the lower 
and at the upper rim, of variable length and containing most of the functional groups (-
CHO, -COOH, -NH2, -NCS, -N3, -C=CH …etc) that are frequently used for the conjugation 
of ligating units. 46,47 
For the synthesis of polyglycosylated structures, such as glycocalixarenes, very efficient 
reactions have to be used to connect glycosides or glycosylated arms to the desired 
scaffold and an excellent control of the stereochemistry, if the anomeric carbon atom is 
involved in the reaction. Only if these conditions are satisfied, it is possible to obtain the 
desired polyglycosylated compounds in good yields, fully glycosylated and with the 
correct stereochemistry.46 The first successful attempt to functionalize a calixarene 
structure with sugars was achieved using a Mitsunobu reaction at the phenolic hydroxyl 
groups of the macrocycle lower rim, though this strategy demonstrated the difficulties in 
controlling the stereoselectivity. On the contrary, a total stereoselectivity was observed, 
obtaining only the β-glycoside bond, in the reaction at the upper rim with thioethyl 
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glycosides and copper(II) triflate. In this case the yields after removal of benzoyl 
protecting groups was around 70%.48,49  
In order to prevent the formation of complicated mixtures of diasteroisomers, saccarides 
units are equipped, in general, with linkers terminating with reactive group, used for the 
conjugation with the multivalent scaffold.  
Reaction belonging to the so called “Click Chemistry”50,51 are largely used: the conjugation 
between amines and isothiocyanate groups to give thiourea units, and the 1,3-dipolar 
cycloaddictions catalyzed by copper(II) salts, called copper-catalyzed azide-alkyne 
cycloaddiction (CuAAC). 52 
 
 
Figure 1.9 Examples of  “Click Chemistry” obtained glycocalixarenes. 
 
The conjugation via amine-isothiocyanate condensation is carried out in mild condition, 
giving high yields and lack of byproduct of partial functionalization or poisoning metal 
catalysts.53 For what concerns the CuAAC the formation of the 1,3-disostituted triazole 
ring is selective and allows the formation of glycocalixarenes such the one in figure 1.9.54,55 
This reaction takes place between a calixarene adorned with alkyne or azide groups at the 
end of variable chains and saccharide bearing azide or alkyne moiety. The use of 
microwaves activation was demonstrated to have positive effect on yields and reduction 
of both reaction time and byproducts. 54,55 
The ability to interact with lectins is the origin of most biological activity of 
glycocalixarenes.46,47 These multivalent carbohydrate-binding proteins preserve their 
ability to selectively recognise the natural saccharide ligands, although the latter ones are 
oﬀered to the lectin in a rather crowded display, often even hindered by the presence of 
the macrocyclic structure.  
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Particularly useful is the possibility to obtain calixarenes of different sizes for studying the 
multivalent recognition processes of natural macromolecules such as lectins, because it 
makes it relatively easy to get small libraries of glycocalixarenes that possess different 
conformational properties and valency. This allows to evaluate how a different number 
and presentation geometry of the sugar affect the binding activity. This effect has been 
well and extensively shown in a series of galactosyl- and lactosylthioureido calix[n]arenes 
(fig. 1.10) synthesized and studied as inhibitors of VAA plant toxin and human Galectins, 
specifically Galectin-1, -3 and -4 belonging to the three different sub-groups, in the order 
proto-type, chimera-type and tandem-repeat-type, respectively. 56  
 
 
Figure 1.10 Schematic representation of glycocalixarenes (adapted from ref. 46) 
 
The inhibition efficiency was proved to be strongly dependent on the structure of the 
glycocalixarene scaffold. In fact, through fluorescence assisted cell sorting test, it was 
observed that the larger and more conformationally mobile lactosyl calixarenes (f and h) 
are very efficient toward Galectin-4. Furthermore the 1,3-alternate derivative j resulted to 
be the best inhibitor for Galectin-1, and the cone glycocalixarene b, having the same 
valency but different presentation of lactoside units, is the worst inhibitor. The exact 
opposite situation was found toward Galectin-3 for the two tetravalent compounds, being 
the cone isomer b the best and the 1,3-alternate isomer j the worst inhibitor. These results 
strongly support the idea that calixarenes offer unique opportunities in design 
glycoclusters for the effective and selective binding of Galectins. 
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1.6 Magnetic Nanoparticles 
 
Magnetic materials, based on metals such as iron, cobalt and nickel or metal oxides, have 
been involved in diﬀerent ways in the development of modern nanotechnology.  
In most cases, magnetic nanoparticles (MNPs) smaller than the single domain limit 
(around 20 nm for iron oxide) exhibit superparamagnetism at room temperature. Meaning 
that the MNPs lose their magnetism below their Curie temperature and that are composed 
of a single magnetic domain. The superparamagnetism has in particular applications in 
ferroﬂuids due to the tunable viscosity, in data analysis and in medicine. All these 
disciplines need to be provided with speciﬁc kind of MNPs, stable in diﬀerent conditions 
and with diﬀerent geometries and physical properties. In this context, nanotechnology 
allows for controlled synthesis and functionalization of materials at nanometre scale.57 
The microscopic origin of magnetic properties in matter lies in the orbital and spin 
motions of electrons,58 whose spin and angular momentum are associated with a magnetic 
moment. The interaction between the magnetic moments of atoms from the same material 
causes magnetic order below a certain critical temperature. We can classify bulk materials 
on the basis of these interactions and their inﬂuence on the material behaviour in response 
to magnetic ﬁelds at diﬀerent temperatures (e.g. ferromagnetism, ferrimagnetism, etc.).59 
Bulk magnetic materials are composed of magnetic domains, that are regions within 
which there is an alignment of the magnetic moments. If, as in the case of MNPs, the 
volume of the material is reduced, the magnetic properties are no longer similar to bulk 
materials because a situation in which just one domain is reached occurs.  
Due to their small volume, MNPs usually present superparamagnetic behaviour, meaning 
that the thermal energy may be enough to change spontaneously the magnetisation within 
each MNP. In other words, the magnetic moment of each MNP will be able to rotate 
randomly just because of the temperature inﬂuence. For this reason, in the absence of an 
electromagnetic ﬁeld the net magnetic moment of a system containing MNPs will be zero 
at high enough temperatures (fig. 1.11). However, in the presence of a ﬁeld, there will be a 
net statistical alignment of magnetic moments, analogous to what happens to 
paramagnetic materials, except that now the magnetic moment is not that of a single atom 
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but of the MNPs containing various atoms which can be up to 104 times larger than that of 
a paramagnetic material.57  
 
 
Figure 1.11 Schematic representation of a superparamagnetic particle.57 
 
This property, marked by the lack of remanent magnetisation after removal of external 
ﬁelds, enables the MNPs to maintain their colloidal stability and avoid agglomeration, 
which is important for biomedical applications. 57 
The main parameters to characterize magnetic properties such as coercivity (Hc) and 
susceptibility (w) are: composition, crystallographic structure, vacancies and defects, and 
magnetic anisotropy. Additionally for MNPs on the nanoscale range, the shape and size 
also determine their magnetic behaviour. The magnetic anisotropic energy barrier from 
the spin-up state to the spin-down state of the magnet is proportional to the product of the 
magnetic anisotropy constant (K) and the volume of the magnet. Therefore, 
superparamagnetism depends on the size of the MNP. In general, smaller is the size of the 
MNP, lower its transition temperature from ferromagnetic to superparamagnetic 
behaviour will be. Size reduction so reﬂects in the enhancement of the relative 
contribution of surface eﬀects. 60 Besides size eﬀects, the MNP shape is known to strongly 
inﬂuence K and again the magnetic anisotropic barrier and the whole magnetic properties 
of the nanomaterial. In general, large magnetic moments are preferred for most 
applications, as this would reduce the amount of MNPs needed. However, when dealing 
with biological applications, biocompatibility reaches great importance, as the 
accumulation or toxic eﬀects of the MNPs need to be reduced as much as possible. 
Therefore, most of the time a balance between larger magnetic moments and 
biocompatibility needs to be reached. This is why iron-based MNPs are often preferred 
compared to others based on more toxic transition metals. 61  
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The MNP coating is also a key element in order to speciﬁcally bind other compounds to 
the MNPs or to prevent agglomeration, but it will also aﬀect the magnetic properties of the 
MNPs due to the high speciﬁc surface area and the large amount of atoms at the surface. 
In fact, the diﬀerences in the nature of the coupling agent and in the type of interaction 
between the ligand and the MNP surface would explain the diﬀerences in the 
magnetisation values. 
The application of an external alternating magnetic ﬁeld (AMF) to MNPs leads to the 
production of energy, in the form of heat, if the magnetic ﬁeld is able to reorient the 
magnetic moments of the MNPs.62 Such an eﬀect can be exploited to use MNPs as 
mediators in magnetic hyperthermia. In bigger multidomain MNPs, this reorientation is 
produced through the movement of domain walls, while in small mono-domain MNPs, 
the reorientation of the magnetic moments can occur due to the rotation of the moment 
within the MNP, overcoming their anisotropy energy barrier (Ne’el loss), or the 
mechanical rotation of the MNPs that will create frictional losses with the environment 
(Brown loss).47 
Magnetic ferrites for biomedical use are most commonly prepared by hydrolytic synthesis, 
with particular reference to coprecipitation techniques. A widespread approach relies on 
the Massart method,63 where magnetite is obtained by alkaline coprecipitation of 
stoichiometric amounts of ferrous and ferric salts (usually chlorides). The experimental 
parameters aﬀecting this process, which involves the formation of intermediate hydroxyl 
species, such as temperature, pH, concentration of the cations and nature of the base, have 
been studied in order to vary the average MNP size in the range from 3 to 20 nm. 
The coprecipitation approach oﬀers a wide range of advantages including: the use of 
cheap chemicals and mild reaction conditions, the possibility to perform direct synthesis 
in water, the ease of scale-up.  
The application of MNPs in biology requires their stability in solutions containing high 
concentrations of proteins and salts, as well as in cell culture media. MNPs suitable for this 
application can be synthesized following diﬀerent approaches that will lead to hydrophilic 
surfaces. The two possible approaches to render MNPs surface hydrophilic are: to 
exchange the surfactant for another ligand molecule that on the one end carries a 
functional group that is reactive toward the MNP surface and on the other end a 
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hydrophilic group, or to add a second layer of an amphiphilic molecule or polymer that is 
solely stabilized around the ﬁrst layer by hydrophobic effects. The latter method is more 
universal and agglomeration during the coating process is almost avoided though on the 
other hand, the hydrodynamic radius is inevitably increased.56 
In literature, it is possible to find some examples on MNPs covalently functionalized with 
different biomolecules in order to achieve different results. For example, MNPs can be 
coated with a thick dextran layer stabilized by crosslinking and functionalized with amino 
groups, useful to covalently anchor affinity ligand creating nanoswitches, as was 
explained by Weissleder at al.  in 1999.64 Those nanoswitches have the ability to undergo 
reversible assembly in presence of specific molecules that are selectively recognized by the 
affinity ligands immobilized on the surface. This approach was used later to quantitatively 
determine analytes of different nature, such as glucose65 or calcium66 in solution, attaching 
proper affinity ligands.  
It is also possible to detect and sequester bacteria, for istance, such as Gram-positive 
bacteria even at ultralow concentrations using a vancomycin-conjugated FePt magnetic 
nanoparticles.67 Using a silica-coated MNPs covered with sugars (glucose and galactose) 
E.coli strains could be detected,68 while MNPs coated with sugars (mannose, galactose, 
fucose and sialic acid) were used to localize certain tumor cells. 69 
 
 
1.7 Gold Nanoparticles 
 
Colloidal gold nanoparticles (AuNPs) had technological application since ancient times 
due to their optical properties, in particular for staining glass. Systematic investigations on 
gold colloids could be traced back to the days of Faraday, though the breakthrough of 
their use for biological applications took place only in the last decade.70 
AuNP absorbs and scatters light intensely at its surface plasmon resonance (SPR) 
wavelength region and such properties make AuNPs as one of the most valuable optical 
probes for sensing applications. 71 The SPR wavelength of gold nanoparticles can be tuned 
from the visible to the near IR region by changing the size and shape of the gold 
nanoparticles. The strong absorption or scattering of AuNPs in the visible light region 
makes them easily observable by naked eye or detectable by inexpensive instruments. The 
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possibility of tuning the SPR band of AuNPs (including nanorods, shells, stars, and other 
shapes) to the near IR region makes them promising materials for in vivo imaging and 
analysis. The optical properties of AuNPs are further dependent on the surface chemistry 
and the inter-particle interactions and are governed by their unique localized surface 
plasmon resonance (LSPR), which is the collective oscillation of the nanostructure’s 
conduction band electrons in resonance with the incident electromagnetic ﬁeld. 72 
Upon analyte binding, the surface plasmon resonance of the AuNPs changes due to the 
surface chemistry change, or inter-particle interaction modification. This surface plasmon 
resonance change of AuNPs can then be detected either by light absorption or light 
scattering techniques. A typical AuNP contains two structural components: the metal core 
and the surface coating. The detection methods as mentioned above are mainly based on 
the property and property changes of the metal core. Since nanoparticles have a large 
surface area/volume ratio and the surface chemistry can be well controlled, the surface 
coating layer of AuNPs provides additional opportunity for detection and sensing of 
analytes (fig. 1.12). 
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Figure 1.12 Illustration of six detection mechanisms using the optical properties of AuNPs. (A) LSPR 
concept: (1) Irradiation of the gold nanoparticles gives rise to a collective oscillation of their conduction band 
electrons resulting in a plasmon absorption in the visible range of the electromagnetic spectrum. (2) This 
plasmon resonance is sensitive to changes in the local environment, for example the binding of biomolecules. 
(B) (1) When nanoparticles are irradiated with laser light, they will scatter the light elastically in all 
directions. By monitoring the change in the scatter pattern the diameter of the solid nanoparticles can be 
deduced. (2) When biomolecules are attached on the nanoparticle surface the size increase can be monitored. 
(C) Detection using the surface chemistry and ligands of AuNPs. (1) Signal ampliﬁcation based on the large 
number of DNA strands (bar-codes) released from the AuNPs. (2) Surface chemistry-controlled reversible 
biomolecular binding to AuNPs in a competitive assay. (D) (1) Normal Raman scattering is inherently weak. 
(2) When biomolecules of interest are bound to nanoparticles, the Raman signal can be enhanced due to the 
enhanced electromagnetic ﬁeld which is excited or due to a charge transfer mechanism. When molecules are 
attached to AuNPs their properties can change. (E) Metal enhanced ﬂuorescence can occur when a 
ﬂuorophore is placed at a ﬁxed position from the metal nanoparticle surface. (F) When the ﬂuorophore is in 
short or direct contact with the metal nanoparticle surface quenching will occur. In this case, a competitive 
assay format is often used for the target analyte detection.73 
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The synthesis of gold nanoparticles with diameters ranging from a few to several 
hundreds of nanometres is well established in aqueous solution as well as in organic 
solvents. In typical syntheses, gold salts such as AuCl3 are reduced by the addition of a 
reducing agent which leads to the nucleation of Au ions to nanoparticles. In addition, a 
stabilizing agent is also required which is either adsorbed or chemically bound to the 
surface of the Au nanoparticles. This stabilizing agent (often also called a surfactant) is 
typically charged, so that the equally charged nanoparticles repel each other so that they 
are colloidally stable.74 Similar synthesis routes can also be performed in organic solvents, 
75,76 though in this case the reducing agent is diﬀerent from the stabilizing agent. For 
particles dispersed in organic solvents, frequently surfactants based on hydrophobic 
alkane chains are bound to the particle surface in order to provide colloidal stability. 
As in the case of MNPs, also for AuNPs a surface modification is possible after synthesis. 
The stabilizer molecules can be replaced by other stabilizer molecules in a ligand exchange 
reaction. As thiol moieties bind with high aﬃnity to gold surfaces, most frequently thiol-
modiﬁed ligands are used which bind to the surface of the Au particles (which are by 
several groups also called ‘‘monolayer-protected clusters’’) by formation of Au–sulfur 
bonds.77 It it also possible to change the particles surface taking advantage of lipophilic 
interaction between the lipophilic stabilizer of the NPs and the hydrophobic part of an 
amphiphilic receptor. Ligand exchange in fact allow, for example, the transfer of Au 
particles from an aqueous to an organic phase (and vice versa) by exchanging hydrophilic 
surfactants with hydrophobic surfactants (and vice versa).78 
Many examples of AuNPs covered with biomolecules can be found in literature. Most of 
the time the approach used is a covalent one, but some cases of use of non-covalent 
interaction was reported.  
The surface of AuNPs could be covered with amines or quaternary ammonium salts, in 
order to bind DNA thanks to electrostatic interactions, and, due to the surface 
modification with a photoactive liker, are also able to release the DNA after UV 
irradiation.79 The most commonly used biomolecules in derivatizing gold surface of NPs 
are antibodies. Such molecules can be adsorbed on the surfaces by using formation of 
covalent bonds or taking advantage of hydrophobic or ionic interactions.80 Some other 
examples describe how the gold surfaces could be covered with a dense core of synthetic 
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oligonucleotides,81 with oligopeptides82 or both.72 Recently, lipids joined other biomolecule 
in AuNPs funtionalization. Lipids are used to form by-layer on AuNPs, the first layer 
adsorbed on the surface using a thiolated lipid and the second layer attached to the 
previous one thanks to hydrophobic effects.83 There are also some examples of 
glycosylated AuNPs, where the surface is covalently covered with lactose, in order to 
study and confirm carbohydrate-carbohydrate interaction in water,84 or a mixture of 
saccharides, used for example for preparation of potential anticancer vaccines,85 or with 
di- tri- tetra- or more mannose units to intervene against HIV infection. 86 
 
 
1.8 Luminescent Platinum(II) Complexes 
 
Fluorescence has become one of the most powerful and extensively used tools in cell 
biology, physiology and related areas of the biomedical sciences. 87 Widely utilised for the 
sensitive detection of species in “in vitro” bioassays, often in conjunction with 
immunological methods, the applications of fluorescence have been greatly extended by 
coupling it to optical microscopy.88,89,90 This combination has allowed huge advances to be 
made in visualising, for example, intracellular structure and function, including those of 
live cells and tissue sections.91,92 Most recently, the use of low-energy red and near-
infrared light, to which biological tissue is relatively transparent, has led to fluorescence 
methods being applied even to animal specimens.93,94 
Three key features of fluorescence render it especially attractive. The ﬁrst is the exquisite 
sensitivity that has become possible, thanks to the extraordinarily high efﬁciency with 
which light can be detected.95 Secondly, the wavelength range of visible light is such that 
spatial resolution of around 1µm is easily achievable with simple optical microscopes, a 
length-scale that is compatible with the study of many intracellular structures. Finally, the 
timescale of light emission is fast, typically on the nanosecond to microsecond timescale. 
One of the attractions of complexes based on cyclometallating ligands, for example, is the 
possibility to have facile colour tuning. For instance, in complexes such as [Ir(ppy)2(bpy)]+ 
and Pt(dpyb)Cl (fig. 1.13), the HOMO and LUMO are primarily localised on mutually 
different parts of the molecule.96,97 The HOMO is based largely on the metal and 
metallated aryl units, whereas the LUMO is based on the pyridyl rings. This allows their 
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energy levels to be tuned essentially independently of one another, and complexes 
emitting across the spectrum are readily possible. This contrasts with many ﬂuorescent 
organic structures where control over colour is more limited. 
 
 
Figure 1.13 Structures of some of the main types of core units used in imaging with metal complexes to date: 
(a) [Ru(bpy)3 ]2+ ; (b) the Ru(bpy)(CO)3 X; (c) the cis-[Ir(ppy)2(bpy)]+ unit common to many iridium-based 
imaging agents investigated; (d) Pt(dpyb)Cl, an example of a cylometallated platinum(II) complex that has 
been used for imaging, incorporating a strong-ﬁeld tridentate ligand. 
 
A second point relates to synthetic issues. Modiﬁcation of many ﬂuorescent organic 
structures can be demanding, whereas many metal complex types can be prepared using 
well-deﬁned strategies, often involving stepwise introduction of different ligands. 
Puriﬁcation is also often straightforward via crystallisation or chromatography. One 
argument sometimes raised against the use of metals such as iridium and platinum is their 
high cost. However, for an application such as imaging, the amounts of material in 
question are minimal, and the cost of the metal is often only a relatively minor fraction of 
the total synthetic costs. 
A third point relates to the difference in energy between the absorbing and emitting states. 
For most organic ﬂuorophores, the state in question is the same (normally the S1 state) and 
the difference in energy between the lowest energy absorption band and the emitting band 
(the Stokes’ shift) is often small, arising from the reorganisation of solvent molecules that 
occurs to stabilise the excited state after absorption and prior to emission. For triplet-
emitting metal complexes, the emission emanates from a state (the triplet state) different  
from that which is excited by absorption of light (normally singlet states), and spin 
correlation effects stabilise the former with respect to the latter. Overlap of absorption and 
emission is almost never a problem for such complexes. Probably the really key distinction 
of luminescent metal complexes for bioimaging lies in the longer lifetimes of emission: 
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lifetimes of triplet-emitting transition metal complexes are typically two to three orders of 
magnitude longer than those of organic ﬂuorophores.98 In bioassays and bioimaging, long-
lived probes can allow the elimination of background ﬂuorescence from biological 
molecules on the basis of time.99,100 
There are also potential disadvantages of using long-lived emitters. One is that the long 
lifetime allows more time for excited-state quenching processes to occur. For example, the 
triplet excited states of transition metal complexes may be efﬁciently deactivated by 
dissolved molecular oxygen in solution, often leading to the formation of singlet 
oxygen.101 The high reactivity of singlet oxygen with organic molecules and biological 
entities can lead to phototoxicity, a desirable feature in photodynamic therapy, for 
example,102 but clearly not for imaging purposes. Nevertheless, research to date suggests 
that singlet oxygen production is not necessarily problematic in imaging work, possibly 
because the diffusion rate of oxygen in the cell and its interaction with metal complexes 
bound to large biomolecules is reduced. 
In order to be realistic candidates for imaging in life sciences, luminescent probe molecules 
should ideally satisfy a number of requirements: high extinction coefﬁcient in the visible 
range, leading to population of the emissive excited state close to 100% yield; high 
emission quantum yield; solubility in water; high cell permeability; low cytotoxicity; high 
chemical stability, i.e. maintaining its chemical integrity in the imaged object; and high 
photostability, i.e. the compound should not undergo photobleaching when irradiated 
during use, as happens for many of the commercial labels used currently. 
Of course to achieve all the criteria in the list above is clearly unrealistic, but each new 
probe should be tensioned against at least some of them.103 
 
 
Figure 1.14 Some examples of Pt(II) complexes.104 
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Platinum(II) differs from the other elements – Ru(II), Re(I) and Ir(III), in that it is a d8 
metal ion, and hence normally adopts a 4-coordinate square planar geometry as opposed 
to the distorted octahedral complexes of the d6 metal ions. The presence of strong- ﬁeld 
ligands is particularly important in the design of emissive platinum(II) complexes, in 
order to ensure that metal-centred d–d states – which are highly distorted compared to the 
ground state and hence potentially deactivating – are displaced to high energy. 105 The 
most brightly emissive platinum(II) complexes, including those which have been 
investigated for bioimaging, containg cyclometallating ligands such as 2-phenylpyridines 
or their tridentate analogues (fig 1.14), as well as strongly-donating acetylide ligands in 
conjunction with accepting di- or tri-imine ligands like bpy or tpy.106,107,108 From the point 
of view of interactions with biological molecules and intrinsic biolocalization within a cell, 
the square planar geometry might lead one to anticipate quite different behaviour for 
platinum(II) complexes compared to those of the other elements.109 
Importantly from the point of view of applications, the emission can be tuned over a very 
wide spectral range (sky-blue to red), without signiﬁcantly compromising the 
luminescence quantum yield, through simple substitution of the central aryl or lateral 
pyridyl rings (fig. 1.15).110,111,112 
 
 
Figure 1.15 Shows how the emission spectra of the Pt(N^C^N) class of complex can be tuned from that of 
Pt(dpyb)Cl (a, black line), either to longer wavelengths through the introduction of electron-donating alkyl 
or aryl substituents at the 4-position (c–f), or to shorter wavelengths using an electron-withdrawing 
substituent ester group at this position (b, light blue line)/electron-donating methoxy substituents in the 
pyridyl rings (i, purple line).113 
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In these platinum(II) complexes, one often refers to the ancillary ligand to indicate the 
non-chelating ligand of platinum(II), often a chloride or a pyridine moiety. The use of 
ancillary ligands often allow to a quite easy modification of the ancillary ligand itself, for 
example, by simply functionalizing the pyridine moiety in in one of its positions and 
giving the possibility to enhance or tune the solubility, changing the uptake property and 
biological activity and the aggregation ability. In fact, as mentioned before, the most 
important part for emitting property is the tridentate ligand.  
Triplet emitters based on platinum(II) can form aggregates or eximers, causing shifts in the 
emitted wavelengths and affecting the photoluminescence quantum yield (PLQYs) 114. Is 
well known that terpyridine ligands and their N^C^N and N^N^C analogues have been 
coordinated to platinum(II), leading to neutral, mono-, or doubly charged species, some of 
which display bright luminescence. They can form supramolecular structures, such as 
nanowires, nanosheets, and polymeric mesophases, with interesting optical and 
supramolecular properties.115,116,117,118 
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2.1 Introduction 
 
During the last two or three decades we have witnessed remarkable efforts in research and 
development activity aimed at obtainment of optical sensors for the measurement of 
chemical and biological species. 
Sensors for analytes of biological interest that rely on rapid and portable screening 
techniques have been of interest to identify harmful toxins for food safety1,2 or to detect 
chemical or biological agents that could be used in bioterrorism.3,4,5 They are also of 
interest for research purposes in areas of biophysics and pharmaceutical sciences.  
 
Galectin-3 is a member of the lectin family, of which 15 mammalian Galectins have been 
identified. Galectin-3 is approximately 30 kDa and, like all Galectins, contains a 
carbohydrate recognition binding domain (CRD) that enables the specific binding of β-
galactosides. This protein has been shown to be involved in a series of fundamental 
biological processes such as cell adhesion, cell activation, cell growth and differentiation 
and apoptosis. Galectin-3 has been demonstrated to be involved in cancer, inflammation 
and fibrosis, heart disease, and stroke. Studies have also shown that the expression of 
Galectin-3 is linked to a variety of processes associated with heart failure, including 
myofibroblast proliferation, fibrogenesis, tissue repair, inflammation, and ventricular 
remodeling.6 Elevated levels of Galectin-3 have been found to be significantly associated 
with higher risk of death in both acute decompensated heart failure and chronic heart 
failure populations. The roles of Galectins and Galectin-3, in particular, in cancer have 
been heavily investigated. Of note, Galectin-3 has been suggested to play important roles 
in cancer metastasis. Remarkably interesting is the intrafamily selectivity, that is the ability 
by an inhibitor to block Gal-3, for instance, but not Gal-1. This property seems quite 
important since Galectin-1 acts as anti-inflammatory agent,7 while Galectin-3 has a pro-
inflammatory activity8 and, even more interestingly, Galectin-3 can act as competitive 
inhibitor against Galectin-1 which, on the other side, induces anoikis of tumor cells.9 
Considering the important areas of biology in which Galectins are involved, their 
inhibition can therefore have useful consequences. The therapeutic potential for Galectin 
                                                 

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inhibitors as anti-inflammatory and immunomodulation agents can be envisaged, but 
their potential in cancer therapeutics is the most obvious. Many of the biological functions 
of Galectins exploit multivalent binding, and fot this reason multivalent inhibitors that 
take advantage of this inherent ability can have a significant advantage over monovalent 
inhibitors. While inhibition and modulation of Galectin activities is an important goal it is 
also of strategic importance to have cheap and convenient methods for the detection and 
quantification of Galectins in tissues for biological studies and, in the future, in patient 
samples for early diagnosis and prognosis. This is because biological data that link the 
presence of Galectins, and especially Galectin-3, to an increased likelihood of malignacy or 
metastasis, and in specific cases to a reduced survival likelihood, is accumulating rapidly. 
10 
 
SPR biosensing relies on the principle that any changes on the dielectric sensing surface 
will cause a shift in the angle of reflectivity, followed by a detector, in order to satisfy the 
resonance condition. There are different possible configuration that can be used for SPR 
sensing, but regardless of the configuration, environmental changes in the dielectric 
medium cause an alteration to the phase, amplitude, polarization or spectral distribution 
of the incident light, which can be attributed to changes in the propagation constant and, 
hence, changes in the refractive index are detected in real time. The most common use for 
SPR sensing is to evaluate protein-ligand, protein-protein, or nucleotide hybridization 
events. Since it is typically not advantageous to directly deposit biological molecules onto 
surfaces, especially surfaces of inert metals such as silver or gold, surface functionalization 
should be used to create a more functionally active environment and reduce non-specific 
binding on the surface. Protein-carbohydrate interactions can also be monitored by glycan-
modified surfaces. Nickel nitrilotriacetic acid (Ni-NTA) derivatized surfaces are also 
convenient for specific capturing of proteins that have been genetically engineered with an 
N- or C-terminal polyhistidine tag, a common affinity moiety used during protein 
expression and purification processes. 11 
On the other hand, our research group has been working for the last few years on the 
design and synthesis of glycocalixarenes potentially able to interact with lectins of clinical 
interest, such as the VAA (Viscum Album Agglutinin) plant toxin, that acts as potent 
biohazard, and human Galectins, that act as factor in tumor progression and migration.  
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An interesting class of glycoclusters, that showed to be very effective and selective in the 
interaction with human Galectins, is represented by the lactosyl-thioureido-calix[4]arenes 
represented in figure 2.112. 
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Figure 2.1 Examples of lactosyl-thioureido calix[4]arenes. 
 
Cell-binding inhibition assays demonstrated that these compounds present the capacity to 
inhibit the adhesion of Galectins to the surface of tumor cells, and therefore they represent 
good candidates for antiadhesion therapies. For these studies selected human tumor lines 
were used. Binding of biotinylated Galectins to these cell lines was determined by 
quantitative fluorescence detection through a Fluorescence Activated Cell Sorter (FACS-
Scan) by using streptavidin/R-phycoerythrin as indicator. Interestingly, these 
glycoclusters present the ability to selectively recognize different types of Galectins. For 
example the tetralactosylcalix[4]arene in the 1,3-alternate structure (alt-4-Lac[4]Prop, fig. 
2.1) is a potent inhibitor for Gal-1, while it is the worst inhibitor for Gal-3. On the contrary, 
the cone-tetralactosylcalix[4]arene (cone-4Lac[4]Prop, fig. 2.1) is highly effective in the 
inhibition of Gal-3, but shows very low affinity for Gal-1. Similar experiments were 
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performed with the corresponding galactosyl-thioureido-calix[n]arenes, but these 
compounds showed to be less effective than the lacto-clusters. These bioassays pointed out 
the existence of a strict relationship between the stereochemical disposition of the glycosyl 
units around the different calixarenes and their inhibitory activity. Therefore, these 
glycoclusters present the possibility to selectively target the Galectins with an 
unprecedented intra-family selectivity (selectivity for some of the members of this family).  
This is important because, depending on the pathology, different types of these lectins can 
be involved. 
Aim of this study is to find new compounds able to inhibit Gal-3. For this reason we 
synthesize a new class of glycocalixarene functionalized both with galactose and lactose 
units, that are known to be ligands for this type of Galectin. Moreover we decided to use a 
long spacer between the calixarene scaffold and the sugar moiety, a polyethylenglycol 
chain, in order to enhance the water solubility of these compounds and to reduce some 
possible strains due to the interaction.  
In order to study the inhibition ability of these new glycocalixarenes compound we use 
preliminary SPR affinity study with his-tag Gal-3 Ni-NTA chip. Once an effective inhibitor 
for Gal-3 is found, the perspective of this work is to invert the approach, immobilizing the 
calixarene inhibitor on the chip. This would ideally allow to devise a sensor for the 
important analyte Gal-3, hopefully endowed of a high selectivity and sensitivity. 
 
 
2.2 Results and discussion 
 
For the binding test towards the modified Gal-3 three different glycocalixarenes were 
chosen (fig 2.2), which differ in conformation or type of the sugar they are functionalized 
with. Compound 1 and 2 are in cone structure, that means that all the sugars are presented 
on the same part of the macrocycle. Compound 3 is in 1,3-alternate structure, that means 
that the sugar are disposed in two different and opposite direction. The spacer between 
the sugar and the calixarene core is represented by a long polyethylenglycol chain, linked 
to the multivalent scaffold thanks to a triazole ring. The presence of this long 
polyethylenglycol chain could possibly enhance solubility in water and biocompatibility. 
The sugars used for the functionalization are galactose (1) and lactose (2 and 3) (fig 2.2). 
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Figure. 2.2 Structure of glycocalixarene 1-3. 
 
 
2.2.1 Synthesis of the glycocalixarenes  
 
For the synthesis of these glycocalixarenes a “Click reaction” between an azido glycoside 
and an alkyne-functionalized calixarene is used, following the protocol of the so-called 
Copper-catalyzed azido-alkyne cycloaddition reaction (CuAAC) that is characterised by 
extremely high yields and high regioselectivity on the triazole ring formation, with the 1,4- 
isomer highly favoured over the 1,5-attach.13, 14 
Initially, the azido galactoside 6 was synthesized (fig. 2.3). The pentaacetyloxygalactoside 
4 was directly reacted with 2-(2-(2-chloroethoxy) ethoxy)ethanol using BF3·Et2O as Lewis 
acid to promote the glycosylation reaction. To minimize the formation of the α-anomer the 
temperature was initially kept at 0 °C and then slowly allowed to reach room temperature. 
A mixture of the two α- and β-anomers was obtained, however, the separation of the two 
anomers of compound 5 via column chromatography yielded, without particular 
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difficulties, the pure β-compound 5. The 1H NMR spectrum proved the success of the 
glycosylation reaction and of the purification step. Diagnostic is the coupling constant of 
8.0 Hz for the signal of H1 proton at 4.55 ppm, that unambiguously confirmed the presence 
of the product with the desired β-stereochemistry. Once obtained, compound 5 was 
reacted with NaN3 to give the corresponding azido derivative 6 in satisfactory yield (72%). 
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Figure 2.3 Synthesis of the azido galactoside 6. 
 
Amino-calix[4]arene 10 (fig. 2.4) was synthesized according to literature procedures (fig 
2.4).15 p-tert-Butyl-calix[4]arene 7 was alkylated at the lower rim by using propyl iodide in 
the presence of NaH as base to fix the macrocycle in the cone conformation and obtain 
compound 8.16,17 With the subsequent ipso-nitration reaction compound 9 was formed.18,19 
This reaction led to the desired compound 9 in high yields and with complete substitution 
of the tert-butyl groups with nitro functions, as confirmed by 1H NMR that shows the total 
disappearance of the tert-butyl signals at around 1 ppm. By treating compound 9 with 
hydrazine and Pd/C (10%), product 10 was obtained.20 The complete reduction of the 
nitro groups to amines was easily confirmed by 1H NMR spectroscopy, where a broad 
signal at 3.1 ppm, corresponding to the amine groups, appears and an high-field shift for 
the signal of the aromatic protons, compared to that of the nitro derivative 9, is observed. 
(fig. 3.7) 
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Figure 2.4 Synthesis of tetra-amino calix[4]arene 10 
 
Coupling reaction between amino-calix[4]arene 10 and 4-pentynoic acid in presence of 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) led to compound 11 in 66% yield. 
Calixarene 11 resulted to be very soluble in methanol, while it showed almost no solubility 
in CH2Cl2. 
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Figure 2.5 Synthesis of the alkyne calixarene 11 
 
The CuAAC reaction between the tetra-alkyne calix[4]arene 11 and azido-galactoside 6 to 
give glycocluster 12 (fig. 2.6) was performed in DMF and H2O. CuSO4 was used as copper 
source and sodium ascorbate was added as reducing agent. Also thanks to the use of a 
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microwave-assisted procedures21 it was possible to efficiently prepare glycocluster 12, that 
was obtained in 20 minutes at 150 W and 80 °C in 83% yield. No partially functionalized 
compounds or other byproducts were detected in the crude mixtures. Purification by 
column chromatography was necessary just to remove the excess of starting galactoside 
reagents used in the reactions. The 1H NMR spectrum of galactosyl-calix[4]arene 12 
presents a broad signal at 7.75 ppm for the proton of the triazole ring and complete 
absence at 2.27 ppm of the peak for the alkyne group present at the upper rim of the 
reagent 11. 
The deprotection from the acetyl groups was performed via transesterification reaction in 
presence of CH3ONa in CH3OH at room temperature according to the standard Zemplen 
procedure22 (fig. 2.6). Complete deacetylation was achieved in 1 hour, as confirmed by 1H 
NMR spectra of the obtained compound 1, where it is possible to observe the complete 
absence of the acetyl signals between 2.15 and 1.90 ppm. 
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Figure 2.6 Synthesis of the galactosylcalixarene 1 
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Cone-compound 2, similar to compound 1 but functionalized with lactose units, and 
compound 3, that presents lactose moieties connected to a 1,3-alternate calixarene core, 
were obtained using a similar synthetic strategy. 
The first step of their synthesis consisted in the preparation of lactoside derivative 15 (fig. 
2.7). When octa-O-acetyl-lactose 13 was reacted with 2-(2-(2-chloroethoxy)ethoxy)ethanol 
in presence of SnCl4 and CF3CO2Ag, compound 14 was obtained mainly, but not 
exclusively, as β-anomer. Column chromatography purification could anyway yield to 
pure β-compound in 74% yield. The subsequent reaction of chlorinated compound 14 with 
NaN3 led to the corresponding azido derivative 15 in 60% yield after 24 hours.  
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Figure 2.7 Synthesis of the lactoside derivative 15. 
 
1,3-Alternate-tetra-propargyl-calix[4]arene 20 (Alt-tetra-propargyl-calix[4]arene) was 
obtained from the corresponding 1,3-alt-amino-calix[4]arene 19 (fig. 2.8) via reaction with 
EDC in CH2Cl2 and pyridine 7:3 as previously described for compound 11. Amino-alt-
calixarene 19 was synthesized following a three steps procedure from p-tert-butyl-
calix[4]arene 16, that was alkylated at the lower rim with propyl bromide in presence of 
Cs2CO3 in dry CH3CN to fix the macrocycle in the 1,3-alternate conformation,23,24 and 
yielding compound 17. Subsequent ipso-nitration allowed the complete substitution of the 
p-tert-butyl groups with nitro groups, yielding tetranitro derivative 1824, that was then 
treated with hydrazine and Pd/C (10%) to obtain the tetraamino-product 1925.  
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Figure 2.8 Synthesis of the 1,3-alt-tetra-propargyl-calix[4]arene 19. 
 
Azido-lactoside 15 was then reacted with the cone- and 1,3-alternate-tetra-alkyne-
calix[4]arenes (compound 11 and 19, respectively), via CuAAC “click” reaction, as 
previously described for the analogous galacto-clusters, to give respectively cone-
calix[4]arene 20 (fig. 2.9) and alt-calix[4]arene 21 (fig. 2.10) in 45-50% yields. Microwave 
irradiation (150 W, 80 °C) allowed to obtain complete tetra-functionalization in only 40 
minutes reaction. Subsequent deacetylation with Zemplen method led to target 
compounds 2 and 3. 
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Figure 2.9 Synthesis of the cone-lactosylcalix[4]arene 2. 
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Figure 2.10 Synthesis of the 1,3-alt-lactosylcalix[4]arene 3. 
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2.2.2 Expression and purification of Gal-3 
 
His-tag Gal-3 (that is Gal-3 with hystidine tail) was expressed in E. coli BL121 using 
classical methodology of expression heterologous proteins. It was decided to express and 
use Gal-3 in his complete form, and non only its Carbohydrate Recognition Domain 
(CRD), that is the domain responsible for the galactoside binding, as many other group 
did before. 
After induction with IPTG (Isopropil-β-D-1-tiogalattopiranoside), cells had been lysed and 
the proteins had been purified via affinity chromatography using IMAC (Immobilized 
Metal Ion Affinity Chromatography) columns that contains chelated Nickel on the surface, 
able to interact with the hystidines tails on Gal-3.  Purified proteins, at this point, were 
eluted using an excess of imidazole (150 mM). Purification step was confirmed using 
electrophoresis in denaturant condition (fig 2.11). The identity of the proteins was 
confirmed thanks to a digestion on trypsin gel and MS/MS analysis (ESI-MS, Q-trap, 
Applied Biosystem). Molecular weight was confirmed by electrophoresis gel (fig. 2.11, left) 
and the secondary structure thanks to circular dichroism spectra (fig. 2.11, right).  
 
 
Figure 2.11: On the left: elctrophoresis gel of Gal-3, columns 1 e 2 are the crude extract, fractions 4-7 are 
different eluetes of IMAC column with the band of pure Gal-3 protein (approximate molecular weight 30 
kD). On the right: circular dichrosim spectra and thermical unfolding of purified Gal-3. 
 
1 8 2 7 6 5 4 3 
T(° C) 
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This expressed Gal-3 had a hystidine tail that was used to immobilize in a directed way 
protein on the chip surface for SPR measurements. At this point one of the critical point of 
the  synthesis of his-tag Gal-3 came up: how to determine the activity and functionality of 
the expressed and purified Gal-3. In fact there are no standard tests to evaluate the ability 
of Gal-3 to interact with its natural ligands, the only proof that expressed Gal-3 was in 
native conformation was obtained through circular dichroism spectrometric 
measurements. 
Then protein Gal-3, in its complete form, was immobilized on Ni-NTA chips thanks to 
interaction with N-terminal hystidine tails (His-tag). 
 
 
2.2.2 SPR analysis 
 
For a preliminary evaluation of the interaction between the new calixarene 1, 2, 3 and 
immobilized his-tag Gal-3 the sensograms of fig 2.12 were recorded fluxing, over the chip, 
1mM solution of calixarene in 10mM HEPES, 150mM NaCl, 50uM EDTA, 0.005% (v/v) 
Tween 20 at pH 7.4. The Ni-NTA (nitrilotriacetic) chip consists of carboxymethylated 
dextran with covalently immobilized NTA. The NTA molecule chelates metal ions such as 
Ni2+, creating coordination sites that bind to polyhistidine tags. Thereafter the analyte of 
interest is passed over the surface and the binding of the ligand to the his-tag Gal-3 
functionalized chip can be detected (figure 2.12). 
 
Figure 2.12 Interaction between hys-tag Gal-3 and the Ni-NTA chip. 
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Figure 2.13 Sensorgramms obtained with SPR in binding experiment between Gal-3 immobilized on chip 
and glycocalixarenes. 
 
Although the increases of resonance units in the sensogramms (fig 2.13) due to the binding 
with the protein are rather low, the three replicates (fig 2.14) that were obtained always 
show the same identical trend and order of affinity between ligands and protein. 
Compound 2 in the cone structure and functionalized with lactose units seems to be the 
best ligand for gal-3, while glycocalix 3, in 1,3-alternate structure and also functionalized 
with lactose is less efficient in binding the lectin. Calixarene 1, in the cone structure and 
with galactose units, seems not to interact at all.  
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Figure 2.13 Relative affinity of glicocalixarene 1, 2, 5 (conc. 1 mM) towards Gal-3 expressed in term of 
increase of resonance unit (RU). 
 
From these preliminary experiment it seems quite clear that the disaccharide ligand, 
lactose, makes the calixarenes better ligands for Gal-3 compared with the monosaccharide  
galactose; this is clearly consistent with the literature data, that in general confirm that 
monovalent Lactose is a better ligand for Gal-3 than monovalent galactose. Quite 
interestingly, also in these conditions the lactosylcalixarene fixed in the cone structure 
appears to bind better gal-3 than the isomer in the 1,3-alternate structure, confirming the 
data obtained in a series of inhibition experiments of the same lectin in surface-
immobilised asialofetuin and on cells with the lactosylthioureidocalixarenes of figure 2.1.12 
Finally, suspecting that the glycocalixarenes 1-3 might aggregate in aqueous solution due 
to their amphiphilic structure resulting from polar residues (the sugars) and a lipophilic 
part (the calixarene core), we carried out some Dynamic Light Scattering (DLS) 
measurements using 1mM solutions of compounds in buffer 10mM HEPES, 150mM NaCl, 
50uM EDTA, 0.005% (v/v) Tween 20 at pH 7.4 (Tab 2.1).  
 
Compound Micelles size (nm) 
1 309 
2 386 
3 267 
Table 2.1. Hydrodynamic radii of the glycocalix aggregates. 
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The hydrodynamic radii of the glycocalix aggregates show that these compounds indeed 
self-assemble in water solution to form large aggregates and nearly independently from 
their structure (cone or 1,3-alternate) or from the carbohydrate. However, 1,3-alternate 
derivative 3, having a bolamphiphile structure is the one forming the smallest aggregates, 
30% smaller than its cone isomer 2. This latter compound, having lactose units that are 
more hydrophilic than galactose one, having a more amphiphilic structure than 
galactosylcalixarene 1 and hence form larger aggregates. 
 
 
2.3 Conclusions 
 
Three glycocalixarenes 1-3, having long linkers between the glycosyl units and the 
macrocyclic scaffold were studied in the binding to his-tag Gal-3 using SPR. From these 
studies it was possible to notice that the obtained intensity of the signals due to interaction 
between the glycocalixarenes 1-3 and the Gal-3 are quite weak and near to the limit of 
detection of SPR in the used configuration. In fact, the low molecular weights of the 
glycocalixarenes, usually around 2.5 kDa, only slightly exceed the lower limit of detection 
of the used instrument (BIACORE). In spite of the weak intensity of the signals obtained, 
an affinity order for the interaction of ligands 1-3 with the immobilized Gal-3 was 
obtained.  A preference for the lactosyl clusters over the galactose functionalized ones (2 > 
3 >> 1) and a higher efficiency in the binding of Gal-3 shown by the cone derivative 
compared to its isomeric 1,3-alternate counterpart (2 > 3) were observed. This also 
confirms with a different technique what is already known in literature12 that lactosyl-
calixarene are more efficient than galactose-calixarene in Gal-3 binding, and that cone 
isomers are better ligands than the 1,3 alternate ones. 
DLS studies also pointed out a slightly different sizes of the aggregates formed by these 
amphiphiles in water and that might also, in part, influence the affinity studies. 
A possible and future development of these studies could consider the possibility to revert 
the approach and to anchor lower-rim modified lactosyl derivatives of 2 onto the chip, 
thus allowing to obtain a way to sense and quantify important markers of tumors such as 
galectins in biological fluids. 
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2.4 Experimental part 
 
General Information. All moisture sensitive reactions were carried out under nitrogen 
atmosphere, using previously oven-dried glassware. All dry solvents were prepared 
according to standard procedures, distilled before use and stored over 3Å or 4Å molecular 
sieves. Most of the solvents and reagents were obtained from commercial sources and 
used without further purification. Analytical TLC was performed using prepared plates of 
silica gel (Merck 60 F-254 on aluminum) and then, according to the functional groups 
present on the molecules, revealed with UV light or using staining reagents: FeCl3 (1% in 
H2O/CH3OH 1:1), H2SO4 (5% in EtOH), ninhydrin (5% in EtOH), basic solution of KMnO4 
(0.75% in H2O). Merck silica gel 60 (70-230 mesh) was used for flash chromatography and 
for preparative TLC plates. 1H NMR and 13C NMR spectra were recorded on Bruker 
AV300 and Bruker AV400 spectrometers (observation of 1H nucleus at 300 MHz and 400 
MHz respectively, and of 13C nucleus at 75 MHz and 100 MHz respectively). All chemical 
shifts are reported in part per million (ppm) using the residual peak of the deuterated 
solvent, whose values are referred to tetramethylsilane (TMS,  δTMS = 0), as internal 
standard. All 13CNMR spectra were performed with proton decoupling. Electrospray 
ionization (ESI) mass analyses were performed with a Waters spectrometer. Gas 
chromatography mass analyses (GC-MS, electronic impact 70 eV) were recorded on a HP 
6890 Series GC System apparatus, equipped with capillary column DB5 and quadrupolar 
mass selector HP 5973 Mass Selective Detector. Microwave reactions were performed 
using a CEM Discovery System reactor. 
 
General procedure to obtain peracetylated carbohydrates (compounds 4 and 13) 
Sodium acetate (7 eq) was suspended in acetic anhydride (25 eq) and heated to 130 °C. At 
this temperature D-galactose (1 eq) was added batchwise. The mixture was stirred at 130 
°C and checked via TLC (eluent: AcOEt/hexane 1:1). When the reaction was completed, it 
was poured into a flask containing ice and water (5 times the volume of acetic anhydride). 
The mixture was then stirred at room temperature overnight. The solid formed was 
recovered by filtration on Buchner funnel and then purified via trituration in EtOH. 
 
 
Chapter 2 
53 
1,2,3,4,6-Penta-O-acetyl-β-D-galactopyranoside 4 
Sodium acetate (32.0 g, 0.39 mol), acetic anhydride (134 mL, 1.38 mol), D-galactose (10.0 g, 
55.5 mmol) Reaction time: 2 hours. Product 4 was obtained as white solid in 40% yield. 1H 
NMR (300 MHz, CDCl3): δ (ppm) 5.69 (d, 1H, J = 8.2 Hz, H1), 5.42 (dd, 1H, J = 0.9 Hz, J = 
3.4, H4), 5.33 (dd, 1H, J = 8.2 Hz, J = 10.4 Hz, H2), 5.07 (dd, 1H, J = 3.4 Hz, J = 10.4 Hz, H3), 
4.17-4.11 (m, 2H, H6a, H6b), 4.09-4.00 (m, 1H, H5), 2.16, 2.12, 2.04, 1.99 (5s, 15H, Ac). The 
product shows the same physical and spectroscopic properties reported in the literature26.  
 
2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl-(14)-2,3,6-tri-O-acetyl-β-D-
glucopyranoside 13 
Sodium acetate (16.1 g, 0.20 mol), acetic anhydride (68 mL, 0.70 mol), D-lactose (10.0 g, 
28.0 mmol) Reaction time: 18 hours. Product 13 was obtained as white solid in 61% yield. 
1H NMR (300 MHz, CDCl3): δ(ppm) 5.67 (d, 1H, J = 8.4 Hz, H1), 5.34 (d, 1H, J = 3.3 Hz, 
H4’), 5.24 (t, 1H, J = 9.2 Hz, H3), 5.15-4.98 (m, 2H, H2, H2’), 4.93 (dd, 1H, J = 3.3 Hz, J = 10.4 
Hz, H3’), 4.51-4.39 (m, 2H, H1’, H6a), 4.17-4.01 (m, 3H, H6b, H6’a, H6’b), 3.90-3.78 (m, 2H, 
H4, H5’), 3.77-3.70 (m, 1H, H5), 2.18, 2.11, 2.08 (3s, 9H, Ac), 2.07-1.99 (m, 12H, Ac), 1.95 (s, 
3H, Ac). The product shows the same physical and spectroscopic properties reported in 
the literature.27 
 
2-(2-(2-Chloroethoxy)ethoxy)ethoxy-2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 5 
Penta-O-acetyl-β-galactose 4 (0.50 g, 1.28 mmol) and 2-(2-(2-chloroethoxy)ethoxy)ethanol 
(0.28 mL, 1.92 mmol) were dissolved in dry CH2Cl2 (5 mL). The mixture was cooled to 0 °C 
with an ice-water bath and BF3·Et2O (0.80 mL, 6.48 mmol) was added dropwise. The 
mixture, kept under N2, was allowed to slowly reach room temperature and it was stirred 
for 24 h. The reaction was checked via TLC (eluent: AcOEt/petroleum ether 1:1) and once 
finished it was quenched by adding NaHCO3 saturated aqueous solution (20 mL). The 
aqueous phase was extracted with CH2Cl2 (3 x 20 mL). The combined organic phases were 
washed with water (20 mL), dried over anhydrous Na2SO4, filtered and the solvent 
removed under reduced pressure. The residue was purified by flash chromatography 
(eluent: AcOEt/petroleum ether 1:1). Product 5 was obtained pure as a yellow oil. Yield: 
30%. 1H NMR (300 MHz, CDCl3): δ (ppm) 5.36 (dd, 1H, J = 1.0 Hz, J = 3.3 Hz, H4), 5.19 
(dd, 1H, J = 8.0 Hz, J = 10.5 Hz, H2), 5.01 (dd, 1H, J = 3.3 Hz, J = 10.5 Hz, H3), 4.55 (d, 1H, J 
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= 8.0 Hz, H1), 4.17-4.07 (m, 2H, H6a H6b),  3.98-3.87 (m, 2H, H5, β-OCHa), 3.77-3.59 (m, 
11H, β-OCHb, CH2 ethylene glycol chain), 2.13, 2.04, 2.03, 1.96 (4s, 12H, Ac). ESI-MS: m/z 
521.7 [(M+Na)+]. The product shows the same physical and spectroscopic properties 
reported in the literature. 28 
 
2-(2-(2-Azidoethoxy)ethoxy)ethoxy-2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 6 
NaN3 (0.23 g, 3.60 mmol) and tetrabutyl ammonium iodide (0.53 g, 1.44 mmol) were 
added to a solution of galactoside derivative 5 (0.36 g, 0.72 mmol) in dry DMF (5 mL). The 
mixture was stirred at 90 °C for 48 hours under nitrogen atmosphere. ESI-MS analyses 
were performed to monitor the reaction. The solvent was subsequently removed in vacuo 
and the residue redissolved in AcOEt (30 mL). The organic phase was washed with water 
(2 x 30 mL), dried over anhydrous Na2SO4, filtered and the solvent removed under 
reduced pressure. Purification via column chromatography (eluent: AcOEt/petroleum 
ether 1:1) gave pure product 6 as a light yellow oil. Yield: 72%. 1H NMR (300 MHz, 
CDCl3): δ (ppm) 5.37 (dd, 1H, J = 1.2 Hz, J = 4.0 Hz, H4), 5.19 (dd, 1H, J = 8.1 Hz, J = 10.5 
Hz, H2), 5.00 (dd, 1H, J = 4.0 Hz, J = 10.5 Hz, H3), 4.56 (d, 1H, J = 8.1 Hz, H1), 4.19-4.08 (m, 
2H, H6a, H6b), 3.98-3.87 (m, 2H, β-OCHa, H5), 3.81-3.71 (m, 1H, β-OCHb), 3.70-3.59 (m, 
8H, CH2 ethylene glycol chain), 3.87 (t, 2H, J = 5.1 Hz, CH2N3), 2.14, 2.05, 2.04, 1.97 (4s, 
12H, Ac). ESI-MS: m/z 528.2 (M+Na)+. The product shows the same physical and 
spectroscopic properties reported in the literature.29 
 
Cone-5,11,17,23-tetrakis[penta-4-ynoyl-amido]-25,26,27,28-tetrapropoxy-calix[4]arene 11 
4-Pentynoic acid (0.18 g, 1.84 mmol) and EDC (0.35 mg, 1.84 mmol) were dissolved in 14 
mL CH2Cl2 and 6 mL pyridine. The solution was stirred for 30 min at room temperature 
and then amino-calix[4]arene 1015 (0.20 g, 0.31 mmol) were added. The mixture turned 
immediately red. The reaction was stirred at room temperature for 18 hours and it was 
monitored via TLC (eluent: CH2Cl2/CH3OH 9:1). The mixture was then diluted with 
CH2Cl2 (20 mL) and washed with 1M HCl (2 x 20 mL) and water (20 mL). The combined 
aqueous phases were extracted with CH2Cl2 (30 mL). The organic layers were collected 
together and evaporated to dryness. The residue was purified via column 
chromatography (eluent: CH2Cl2/CH3OH 97:3) to give product 11 as a white solid. Yield: 
66%. 1H NMR (300 MHz, CD3OD): δ (ppm) 6.88 (s, 8H, Ar), 4.46 (d, 4H, J = 13.2 Hz, 
Chapter 2 
55 
ArCH2Ar), 3.85 (t, 8H, J = 7.5 Hz, OCH2CH2CH3), 3.11 (d, 4H, J = 13.2 Hz, ArCH2Ar), 2.49–
2.46 (m, 16H, COCH2CH2, COCH2CH2), 2.27 (bs, 4H, C≡CH), 2.00–1.93 (m, 8H, 
OCH2CH2CH3), 1.03 (t, 12H, J = 7.2 Hz, OCH2CH2CH3). The product shows the same 
physical and spectroscopic properties reported in the literature.30 
 
2-(2-(2-Chloroethoxy)ethoxy)ethoxy-2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(14)-
2,3,6-tri-O-acetyl-β-D-glucopyranoside 14 
Octa-O-acetyl-lactose 13 (2.03 g, 3.00 mmol) and 2-(2-(2-chloroethoxy)ethoxy) ethanol (0.65 
mL, 4.50 mmol) were dissolved in 10 mL dry CH2Cl2. CF3COOAg (0.99 g, 4.50 mmol) and 
a 1M solution of SnCl4 (0.91 mL, 9.00 mmol) in dry CH2Cl2 was added dropwise under 
argon atmosphere. The reaction was stirred at room temperature under Ar for 3 hours. 
The reaction was monitored via TLC (AcOEt/petroleum ether 7:3). NaHCO3 saturated 
aqueous solution (30 mL) was subsequently added for quenching. The precipitate was 
filtered off through a Celite pad. The organic phase was collected and the aqueous phase 
was extracted with CH2Cl2 (4 x 30 mL). The combined organic phases were washed with 
water and brine till neutral pH, dried over anhydrous Na2SO4, filtered and the solvent 
removed under reduced pressure. The residue was purified by flash chromatography 
(elution gradient: AcOEt/hexane 65:35 7:3). Product 14 was obtained pure as a yellow 
oil. Yield: 74%. 1H NMR (300 MHz, CDCl3): δ(ppm) 5.32 (d, 1H, J = 3.3 Hz, H4’), 5.17 (t, 
1H, J =  9.3 Hz, H3), 5.08 (dd, 1H, J = 7.9 Hz, J2 = 10.4 Hz, H2’), 4.93 (dd, 1H, J = 3.3 Hz, J = 
10.4 Hz, H3’), 4.87 (dd, 1H, J = 7.8 Hz, J = 9.3 Hz, H2), 4.55 (d, 1H, J = 7.8 Hz, H1), 4.51-4.38 
(m, 2H, H1’, H6a), 4.20-4.00 (m, 3H, H6b, H6’a, H6’b), 3.93-3.79 (m, 2H, H5’, β-OCHa), 
3.78-3.68 (m, 4H, H4, β-OCHb, CH2 ethylene glycol chain), 3.67-3.53 (m, 9H, H5, 3CH2 
ethylen glycol chain, CH2Cl), 2.13, 2.12, 2.10, 2.09, 2.04, 2.02, 1.94 (7s, 21H, COCH3). The 
product shows the same physical and spectroscopic characteristics reported in literature.31 
 
2-(2-(2-Azidoethoxy)ethoxy)ethoxy-2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(14)-
2,3,6-tri-O-acetyl-β-D-glucopyranoside 15 
NaN3 (0.15 g, 2.35 mmol) and tetrabutyl ammonium iodide (0.35 g, 0.94 mmol) were 
added to a solution of lactoside derivative 14 (0.37 g, 0.47 mmol) in dry DMF (10 mL). The 
mixture was stirred at 90 °C for 24 hours under nitrogen atmosphere. ESI-MS analyses 
were performed to monitor the reaction. The solvent was subsequently removed in vacuo 
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and the residue redissolved in AcOEt (40 mL). The organic phase was washed with water 
(2 x 30 mL), dried over anhydrous Na2SO4, filtered and the solvent removed under 
reduced pressure. Purification via column chromatography (elution gradient: 
AcOEt/toluene 65:35  7:3) gave pure product 15 as a light yellow oil. Yield: 60%. 1H 
NMR (300 MHz, CDCl3): δ (ppm) 5.25 (d, 1H, J = 3.3 Hz, H4’), 5.10 (t, 1H, J = 9.3Hz, H3), 
5.01 (dd, 1H, J = 7.9 Hz, J = 10.4 Hz, H2’), 4.87 (dd, 1H, J = 10.4 Hz, J = 3.3 Hz, H3’), 4.87 
(dd, 1H, J = 7.9 Hz, J = 9.3 Hz, H2), 4.49 (d, 1H, J = 7.9 Hz, H1), 4.44-4.36 (m, 2H, H1’, H6a), 
4.09-3.94 (m, 3H, H6b, H6’a, H6’b), 3.88-3.76 (m, 2H, H5’, β-OCHa), 3.71 (t, 1H, J = 9.3 Hz, 
H4), 3.67-3.47 (m, 10H, H5, β-OCHb, CH2 ethylene glycol chain), 3.31 (t, 2H, J = 5.0 Hz, 
CH2N3), 2.06 (s, 3H, COCH3), 2.03 (s, 3H, COCH3), 2.00-1.92 (m, 12H, COCH3), 1.88 (s, 3H, 
COCH3). The product shows the same physical and spectroscopic properties reported in 
the literature.31 
 
Alt-5,11,17,23-tetrakis[penta-4-ynoyl-amido]-25,26,27,28-tetrapropoxy-calix[4]arene 19 
4-Pentynoic acid (90.0 mg, 0.92 mmol) and EDC (176.4 mg, 0.92 mmol) were dissolved in 7 
mL CH2Cl2 and 3 mL pyridine. The solution was stirred for 30 min at room temperature 
and then alt-tetra-amino calix[4]arene 1815 (98.1 mg, 0.15 mmol) was added. The mixture 
turned immediately red. The reaction was stirred at room temperature for 18 hours and it 
was monitored via TLC (eluent: CH2Cl2/CH3OH 9:1). The mixture was then diluted with 
CH2Cl2 (10 mL) and washed with 1M HCl (2 x 10 mL) and water (2 x 10 mL). The 
combined aqueous phases were extracted with CH2Cl2 (30 mL). The organic layers were 
collected together and evaporated to dryness. The residue was purified via column 
chromatography (eluent: CH2Cl2/CH3OH 97:3) to give product 19 as a white solid. Yield: 
65%. 1H NMR (300 MHz, CD3OD/CDCl3 9:1): δ (ppm)  7.31 (s, 8H, Ar), 3.73 (s, 8H, 
ArCH2Ar), 3.24 (t, 8H, J = 7.4 Hz, OCH2CH2CH3), 2.57-2.45 (m, 16H, COCH2CH2, 
COCH2CH2), 2.18-2.14 (m, 4H, C≡CH), 1.34-1.23 (m, 8H, OCH2CH2CH3), 0.67 (t, 12H, J = 
7.4 Hz, OCH2CH2CH3). The product shows the same physical and spectroscopic properties 
reported in the literature.32 
 
General procedure for “click” reactions (compounds 12, 20, 21) 
Calix[4]arene derivative (1 eq) and β-galactoside derivative (6 eq) were dissolved in 2.5 
mL of DMF in a microwave tube. CuSO4·5H2O (0.3 or 0.6 eq), sodium ascorbate (0.6 or 1.2 
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eq) and 0.5 mL H2O were then added. The mixture was heated at 80 °C by microwave 
irradiation (150 W) for a reaction time between 20 and 40 minutes. When the reaction was 
completed (checked via TLC and ESI-MS), it was quenched by addition of water (15 mL) 
and extracted with AcOEt (5 x 15 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered and the solvent removed under reduced pressure. The crude 
was purified by flash chromatography to afford pure the peracetylated glycosyl 
calix[4]arene. 
 
Cone-peracetylated-galactosyl-calix[4]arene 12 
Cone-tetra-alkyne calix[4]arene 11 (38.9 mg, 0.04 mmol), azido galactoside 6 (121.3 mg, 0.24 
mmol), CuSO4·5H2O (3.0 mg 12.0 µmol), sodium ascorbate (4.7 mg, 24.0 µmol). Reaction 
time: 20 min. TLC (eluent: CH2Cl2/CH3OH 95:5). Flash chromatography (elution gradient: 
CH2Cl2/CH3OH 95:5  93:7). Product 12 was obtained as a light yellow solid. Yield: 83%. 
1H NMR (400 MHz, CD3OD/CDCl3 4:1): δ(ppm) 7.75 (bs, 4H, CH triazole), 6.83 (s, 8H, 
Ar), 5.35 (s, 4H, H4), 5.09-5.07 (m, 8H, H2, H3), 4.64 (d, 4H, J = 6.8 Hz, H1), 4.52 (bs, 8H, 
NCH2CH2), 4.41 (d, 4H, J = 13.2 Hz, ArCH2Ar), 4.12-4.10 (m, 8H, H6a, H6b), 4.05-4.02 (m, 
4H, H5), 3.93-3.90 (m, 4H, β-OCHa), 3.84-3.79 (m, 16H, NCH2CH2, OCH2CH2CH3), 3.70-
3.67 (m, 4H, β-OCHb), 3.58-3.53 (m, 24H, ethylene glycol chain), 3.09 (d, 4H, J = 13.2 Hz, 
ArCH2Ar), 3.02 (bs, 8H, COCH2CH2triazole), 2.62 (bs, 8H, COCH2CH2triazole), 2.10, 2.01, 
1.99 (3s, 36H, COCH3), 1.93 (s, 20H, COCH3, OCH2CH2CH3), 0.98 (t, 12H, J = 7.2 Hz, 
OCH2CH2CH3). The product shows the same physical and spectroscopic properties 
reported in the literature.25 
 
Cone-peracetylated-lactosyl-calix[4]arene 20 
Cone-tetra-alkyne calix[4]arene 11 (23.5 mg, 24.1 µmol), azido lactoside 15 (119.8 mg, 0.15 
mmol), CuSO4·5H2O (3.6 mg 14.5 µmol), sodium ascorbate (5.7 mg, 28.9 µmol). Reaction 
time: 40 min. TLC (eluent: CH2Cl2/CH3OH 95:5). Flash chromatography (elution gradient: 
CH2Cl2/CH3OH 97:3  94:6). Product 20 was obtained as a yellow oil. Yield: 46%. 1H 
NMR (300 MHz, CD3OD): δ (ppm) 7.78 (bs, 4H, CH triazole), 6.89 (bs, 4H, Ar), 6.87 (bs, 
4H, Ar), 5.33 (d, 4H, J = 3.3 Hz, H4’), 5.16 (t, 4H, J = 9.2 Hz, H3), 5.10 (dd, 4H, J = 3.3 Hz, J = 
10.4 Hz, H3’), 4.99 (dd, 4H, J = 7.8 Hz, J = 10.4 Hz, H2’), 4.82 (dd, 4H,  J = 7.8 Hz, J = 9.2 Hz, 
H2), 4.73-4.63 (m, 8H, H1, H1’), 4.62-4.40 (m, 16H, H6a, ArCH2Ar, NCH2), 4.21-4.06 (m, 
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16H, H5’, H6b, H6’a, H6’b), 3.94-3.78 (m, 24H, H4, β-OCHa, NCH2CH2, OCH2CH2CH3), 
3.77-3.61 (m, 8H, H5, β-OCHb), 3.60-3.43 (m, 24H, CH2 ethylene glycol chain), 3.12 (d, 4H, J 
= 13.0 Hz, ArCH2Ar ), 3.01 (t, 8H, J = 6.8 Hz, COCH2CH2triazole), 2.63 (t, 8H, J = 6.8 Hz, 
COCH2CH2triazole), 2.14, 2.11 (2s, 24H, COCH3), 2.06-1.87 (m, 68H, COCH3, 
OCH2CH2CH3), 1.02 (t, 12H, J = 7.4, OCH2CH2CH3). The product shows the same physical 
and spectroscopic properties reported in the literature.27 
 
Alt-peracetylated-lactosyl-calix[4]arene 21 
Alt-tetra-alkyne calix[4]arene 19 (11.9 mg, 12.2 µmol), azido lactoside 15 (58.1 mg, 73.2 
µmol), CuSO4·5H2O (1.8 mg 7.3 µmol), sodium ascorbate (2.9 mg, 14.6 µmol). Reaction 
time: 40 min. TLC (eluent: CH2Cl2/CH3OH 95:5). Flash chromatography (elution gradient: 
CH2Cl2/CH3OH 97:3  94:6). Product 21 was obtained as a yellow oil. Yield: 46%. 1H 
NMR (300 MHz, CD3OD): δ (ppm) 7.80 (bs, 4H, CH triazole), 7.33 (bs, 4H, Ar), 7.32 (bs, 
4H, Ar), 5.33 (d, 4H, J = 3.3 Hz, H4’), 5.16 (t, 4H, J =  9.2 Hz, H3), 5.10 (dd, 4H, J = 3.3 Hz, J 
= 10.4 Hz, H3’), 4.99 (dd, 4H, J = 7.8 Hz, J = 10.4 Hz, H2’), 4.82 (dd, 4H,  J = 7.8 Hz, J2-3= 
9.2 Hz, H2), 4.73-4.63 (m, 8H, H1, H1’), 4.58-4.43 (m, 12H, H6a, NCH2), 4.19-4.05 (m, 16H, 
H5’, H6b, H6’a, H6’b), 3.94-3.80 (m, 16H, H4, β-OCHa, NCH2CH2), 3.79-3.63 (m, 16H, H5, 
β-OCHb, ArCH2Ar), 3.60-3.43 (m, 24H, 3CH2 ethylene glycol chain), 3.22 (t, 8H, J = 6.9 Hz, 
OCH2CH2CH3), 3.05 (t, 8H, J = 7.2 Hz, COCH2CH2triazole), 2.71 (t, 8H, J = 7.2 Hz, 
COCH2CH2triazole), 2.11, 2.08, 2.03, 2.02, 2.01, 1.99, 1.91 (7s, 84H, COCH3), 1.38-1.18 (m, 
8H, OCH2CH2CH3), 0.64 (t, 12H, J = 7.4 Hz, OCH2CH2CH3). The product shows the same 
physical and spectroscopic properties reported in the literature.32 
 
General procedure for deacetylation reactions (compounds 1, 2, 3) 
Peracetylated glyco-clusters were dissolved in MeOH and drops of a freshly prepared 
methanol solution of MeONa were added till pH 8-9. The mixture was stirred at room 
temperature for 1 or 2 hours. The progress of the reaction was monitored via TLC and/or 
ESI-MS. When a precipitate was observed, H2O was added to help complete solubilisation. 
Amberlite resin IR 120/H+ was subsequently added for quenching and gently stirred for 
30 min till neutral pH. The resin was then filtered off and the solvent removed under 
vacuum to give pure product. 
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Cone-galactosyl-calix[4]arene 1 
Cone-peracetylated-galactosyl-calix[4]arene 9 (30.0 mg, 10.0 µmol) in 4 mL MeOH. 
Reaction time: 1 hour. TLC (eluent: butanol/acetone/H2O 35:35:15). Product 1 was 
obtained as a white solid. Yield: quantitative. 1H NMR (300 MHz, CD3OD): δ (ppm) 7.81 
(s, 4H, CH triazole), 6.92 (s, 8H, Ar), 4.52 (t, 8H, J = 4.8 Hz, NCH2),  4.45 (d, 4H, J = 13.2 Hz, 
ArCH2Ar), 4.25 (d, 4H, J = 7.2 Hz, H1), 4.00-3.91 (m, 4H, β-OCHa), 3.90-3.78 (m, 20H, H4, 
OCH2CH2CH3, NCH2CH2), 3.77-3.71 (m, 8H, H6a, H6b), 3.70-3.61 (m, 4H, β-OCHb), 3.60-
3.44 (m, 36H, H2, H3, H5, CH2 ethylene glycol chain), 3.11 (d, 4H, J = 13.2 Hz, ArCH2Ar), 
3.01 (t, 8H, J = 7.4 Hz, COCH2CH2triazole), 2.64 (t, 8H, J =7.4 Hz, COCH2CH2triazole), 
2.03-1.87 (m, 8H, OCH2CH2CH3), 1.01 (t, 12H, J = 7.4 Hz, OCH2CH2CH3). The product 
shows the same physical and spectroscopic properties reported in the literature.30 
 
Cone-lactosyl-calix[4]arene 2 
Cone-peracetylated-lactosyl-calix[4]arene 18 (46.0 mg, 11.1 µmol) in 10 mL MeOH. 
Reaction time: 2 hours. Product 2 was obtained as a white solid. Yield: 73%. 1H NMR (300 
MHz, CD3OD): δ (ppm) 7.82 (s, 4H, CH triazole), 6.93 (bs, 4H, Ar), 6.91 (bs, 4H, Ar), 4.54 (t, 
8H, J = 4.5 Hz, NCH2), 4.45 (d, 4H, J = 13.0 Hz, ArCH2Ar), 4.40-4.29 (m, 8H, H1, H1’), 4.00-
3.64 (m, 44H, H4’, H6a, H6b, H6’a, H6’b, β-OCH2, NCH2CH2, OCH2CH2CH3), 3.63-3.39 (m, 
48H, H2’, H3’, H5’, H3, H4, H5, 3CH2 ethylene glycol chain), 3.26 (t, 4H, J = 8.3 Hz, H2), 
3.13 (d, 4H, J = 13.0, ArCH2Ar), 3.02 (t, 8H, J = 7.2 Hz, COCH2CH2triazole), 2.65 (t, 8H, J = 
7.2 Hz, COCH2CH2triazole), 2.08-1.85 (m, 8H, OCH2CH2CH3), 1.02 (t, 12H, J = 7.4 Hz, 
OCH2CH2CH3). The product shows the same physical and spectroscopic properties 
reported in the literature.32 
 
Alt-lactosyl-calix[4]arene 3 
Alt-peracetylated-lactosyl-calix[4]arene 19 (23.0 mg, 5.5 µmol) in 5 mL MeOH. Reaction 
time: 2 hours. Product 3 was obtained as a white solid. Yield: 71%. 1H NMR (400 MHz, 
CD3OD): δ (ppm) 8.07 (bs, 4H, CH triazole), 7.35 (bs, 8H, Ar), 4.64 (t, 8H, J = 4.7 Hz, 
NCH2), 4.37 (d, 4H, J = 7.7 Hz, H1’), 4.35 (d, 4H, J = 8.0 Hz, H1), 4.04-3.95 (m, 4H, β-
OCHa), 3.94-3.68 (m, 40H, H4’, H6a, H6b, H6’a, H6’b, NCH2CH2, β-OCHb, ArCH2Ar), 
3.67-3.39 (m, 48H, 3CH2 ethylene glycol chain, H2’, H3’, H5’, H3, H4, H5), 3.31-3,21 (m, 
12H, H2, OCH2CH2CH3), 3.13 (t, 8H, J = 7.1 Hz, COCH2CH2triazole), 2.79 (t, 8H, J = 7.1 Hz, 
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COCH2CH2triazole), 1.38-1.19 (m, 8H, OCH2CH2CH3), 0.67 (t, 12H, J = 7.4, OCH2CH2CH3). 
The product shows the same physical and spectroscopic properties reported in the 
literature.32 
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3.1 Introduction 
 
Gold nanoparticles (AuNPs) are some of the most extensively studied nanomaterials. 
Because they have many unique optical, chemical, electrical, and catalytic properties, 
AuNPs have attracted enormous attention for biological and chemical sensing 
applications. 1 Although AuNPs have been used for both chemical and biological detection 
and analysis, most of the eﬀorts have been devoted to biological applications. In terms of 
chemical detection, the main interest is more focused on applications in environmental 
protection and homeland security, for example, for the detection of toxic metal ions and 
explosive chemicals. For biological and biomedical applications, the type of target analytes 
spans a wide range of entities from proteins, DNAs, small biomolecules, to 
microorganisms including bacteria and viruses. The use of AuNPs for cancer-related 
detection and analysis is as an extremely active area of research of the last few years.1 A 
signiﬁcant number of studies are indeed aimed to sense and target cancer biomarkers and 
cells. 2,3,4 As one of the most challenging medical problems, cancer causes economic 
burdens to society that outweighs the eﬀect of all other human disease. Innovative 
technologies are needed to bring breakthrough advances to the ﬁeld. It is expected that the 
development of nanoparticle-based technologies to improve cancer diagnosis and 
treatment will continue to remain a hot topic in the future. 
As we already discussed in the previous chapter, glycocalixarene are proved to possess 
good ability to interact with lectins of clinical interest, such as the VAA (Viscum Album 
Agglutinin) plant toxin, that acts as potent biohazard, and human galectins, that act as 
factor in tumor progression.5  
In the literature, it is possible to find a large number of publication discussing 
functionalization of gold nanoparticles with calixarene for many different aims, such as 
templating agent for the formation of the particles,6,7 complexation of small molecule8 or 
ions9. In all the cases, the calixarene scaffold are attached to the surface in a covalent way 
using the most common sulfur-gold bond10,11 or nitrogen-gold bond12, but only a few cases 
report a non-covalent approach13,14 and there are no examples of glycocalixarenes attached 
on AuNPs.  
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Our aim in this project was to found a fast and convenient strategy to obtain new water 
soluble AuNPs functionalized with glycocalixarene scaffolds and therefore exposing a 
carbohydrate coating on the surface of the NP similar to that present on the surface of cells 
and called glycocalyx.  
 
 
Figure 3.1 Representation of the glycocalyx15 and schematic representation of AuNPs functionalized with 
glycocalixarenes. Light blue ellipsoids represent the carbohydrate units. 
 
This special arrangement of carbohydrates could possibly be able to efficiently and 
selectively recognize cells exposing on the outer surface membrane the lectins specific for 
those carbohydrates present on the glycocalixarene-functionalized AuNPs. This study 
should therefore produce the proof-of-principle that calixarenes functionalized with 
proper carbohydrates can be used to adorn nanoparticles and that these structures are 
potentially able to specifically target tumor or unhealthy cells thus suggesting new 
nanomaterials with diagnostic and therapeutic perspectives. In fact, glycocalixarenes 
functionalized with lactose or N-Acetyl-lactose are known to specifically inhibit the 
adhesion of Galectins to the surface of cancer cells.16 Morover, exploiting AuNPs 
properties and, thanks to the ability of calixarenes to complex small drugs in their 
hydrophobic cavity, this approach could also allow to develop new materials as targeted 
drug delivery systems.  
In contrast with what can be found in the literature, where the use of nitrogen or sulfur 
containing calixarene to be grafted on AuNPs is generally needed, we decided here to 
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explore an easier and more convenient approach to functionalize NPs. The presence of the 
sugar units on the calixarene scaffolds, in fact, prompted us to keep the structures of 
glycocalixarenes and their syntheses as simple as possible, thus avoiding all those 
demanding synthetic modifications required to add thiol or amine groups at the lower rim 
of the macrocycles. This novel approach that we are proposing, simply requires the 
noncovalent adhesion of amphiphilic glycocalixarenes on AuNPs covered with 
dodecanthiol chains exploiting hydrophobic effects that reach their maximum importance 
in water solution where such glycocalix functionalised AuNPs are designed to work. 
 
 
3.1 Results and discussion 
 
In this chapter the unprecedented functionalization of AuNPs with glycocalixarenes  is 
presented and discussed. The synthesis of the glycocalixarenes used on AuNPs is also 
described together with that of two phenylthioureido-glycosides (so-called monomers) 
used as monovalent acyclic equivalents of the calixarene glycoclusters. Even if the sugar 
structure varies, some important features are kept constant in the design of these 
glycocluster molecules (fig. 3.2) with respect to the previously studied lactosyl-thioureido 
calix[n]arenes.5 The calixarene scaffold always constitutes the cyclic platform where the 
sugar moieties are covalently anchored and the calixarene structures reported in this 
chapter have always a ring size of 4 phenolic units, are blocked in the cone conformation 
and bear propyl chains at the lower rim. Instead, for the monovalent counterparts, the 
monomers, the phenolic oxygen atom is functionalized with propyl or even with hexyl 
group, in order to increase lipophilicity and to favor the affinity with the AuNPs. The 
thiourea unit was chosen as proper spacer to connect the carbohydrate unit to the 
calixarene backbone, since it can be easily obtained via a “click” reaction of 
aminocalixarenes with the proper glycosyl-isothiocyanates in very high yields and 
practically absence of by-products. Moreover this kind of conjugation does not involve 
bond formation at the anomeric carbon atoms of the glycosides and thus prevents any 
stereochemistry problems during the glycoconjugation reaction. In addition, the hydrogen 
atoms of the two urea NH groups allow further potential hydrogen bonding that could 
increase the binding with the lectins or help the inclusion of drug molecules17,18. The sugar 
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moieties are usually linked to the thiourea groups through β anomeric bonds except that 
in the case of the mannose glycocalixarene (14) where an α bond is present. In fact, in the 
case of mannose, the synthesis of β glycosides or derivatives is extremely difficult and 
takes place in very low yields due to the presence of the OH group in axial-2-position of 
the piranose ring. 
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Figure 3.2 Schematic representation of glycosyl-thioureido calixarenes and their monovalent acyclic 
counterparts called monomers. Light blue ellipsoids represent the carbohydrate units. 
 
In order to easily identify these compounds, whose IUPAC nomenclature results to be 
rather long and complicated, in the thesis the code conf-mScalix[n]arene is used. For each 
compound are indicated: the conformation conf of the calixarene, the number m and the 
type of saccharide S and the size [n] of the macrocycle. 
For the functionalization of the AuNPs we did not used the classical covalent approach 
used by Arduini and Secchi2,3,10 that exploits the functionalization of the lower rim of 
calixarene with long aliphatic chains ending with a thiol group, necessary to form the very 
strong and stable sulfur-gold bonds. In our case, this kind of approach is synthetically 
rather demanding because of the complexity of the synthesis of a calixarene functionalized 
at the upper rim with a carbohydrate and at the lower rim with a primary chain. Therefore 
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we decided to use a completely different and new approach, characterised by the 
noncovalent binding, via hydrophobic effects, between glycocalixarene and AuNPs. In 
fact, glycocalixares are amphiphilic molecules: the upper rim, characterized by the 
presence of the several hydroxyl groups of the sugars, represents the polar part while the 
aromatic core of the calixarene and the aliphatic chains on the lower rim represent the 
apolar counterpart. Taking advantage of the amphiphilic characteristic of these 
glycocalixarenes it seemed feasible to anchor them on particles covered with a liphophilic 
alkyl layers thanks to strong hydrophobic effects between the apolar scaffold of the 
calixarene and the apolar surface of the AuNPs. This  functionalization strategywill also 
direct the carbohydrate moieties towards the exterior of the AuNP making them water 
soluble and potentially available to interact with biological macromolecular structures.  
 
 
3.2.1 Syntesis of the new cone-glycocalixarenes 
 
In the perspective of specifically targeting different cells, we decided to synthesize a new 
cone-4Man-calix[4]arene and to re-synthesize the already studied cone-4Gal-5 and cone-
4GlcNAc-calix[4]arene19. For the synthesis of the two already known compounds the 
synthetic strategy5, found in literature shown in figure 3.3, was used. 
The thiourea unit was used as proper spacer to connect the carbohydrate units to the 
calixarene backbone since it can be easily obtained via a “click” reaction of 
aminocalixarenes with the proper glycosyl-isothiocyanates in very high yields and 
pratically absence of by-products.20 
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Figure 3.3 Reaction schemes for the synthesis of Gal and GlcNAc functionalized cone-calix[4]arene 
 
To synthesize compound 9 (fig 3.4) we used the same approach as illustrated in scheme 
3.2. This molecule is blocked in the cone conformation and functionalized at the upper rim 
with four units of Mannose (fig 3.4). Differently from the previous case, the mannose 
glycocalixarene (9) an α bond is present. In fact, in the case of mannose, the synthesis of 
glycosyl-β-isothiocyanate or other β-glycoside derivatives is extremely difficult and takes 
place only in very low yields due to the presence of the axial OH group in 2-position of the 
piranose ring. 21 
Mannose is well-known to be a biologically relevant saccharide that is found to be 
recognized from Mannose-binding lectin (MBL), also called mannose-binding 
protein(MBP), a lectin that is instrumental in innate immunity.22  
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Figure 3.4 Cone- 4man-calix[4]arene 9. 
 
Tetraamine-tetrapropyl-calix[4]arene 420 and peracetylated Man-α-isothiocyanate 3 were 
prepared and conjugated thanks to the isothiocyanate-amine “click” reaction. The 
synthesis of compound 3 started with the reaction of commercially available mannose 1 
with hydrobromic acid and acetic acid in acetic anhydride, to give the peracetylated  
compound 2. In one step it was possible to achieve simultaneously the acetylation of the 
hydroxyl groups of the carbohydrate and the introduction of a bromine atom in anomeric 
α position.23 This reaction leads exclusively to the α isomer, as confirmed by the 1H NMR 
spectrum, where it is possible to observe the presence of a doublet signal at 6.28 ppm with 
a coupling constant of 1.4 Hz, diagnostic for the α anomer. Once compound 2 was isolated 
by using potassium isothiocyanate and tetrabutylammonium hydrogen sulfate in 
acetonitrile the mannopyranoyl-α-isothiocyanate 3 is obtained (fig 3.5) in just one step24.  
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Figure 3.5 Synthetic pathway to mannopyranosyl-α-isothiocyanate 3. 
 
Mannose derivative 3 was then conjugated to the calix[4]arene core 4 through the 
formation of a thiourea group (fig. 3.6). This “click” reaction gave compound 5 in high 
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yield (65%), and the purification was necessary only to remove the excess of mannosyl 
isothiocyanate used. NMR analyses confirmed the success of the reaction.  
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Figure 3.6 Synthesis of the glycosylcalixarene 6. 
 
The 1H NMR spectrum (300 MHz, MeOD, fig. 3.7) of compound 5 shows the presence of 
the thiourea NH protons at 6.75, and of two doublets at 4.47 and 3.24 ppm attributed to the 
axial and equatorial protons of the calixarene methylene bridge, respectively. From these 
data we could conclude that the calixarene, in the cone structure, had a C4 symmetrical 
substitution at the upper rim with four identical saccharide units. The anomeric protons, 
resonating at 6.06 ppm, confirmed that the sugar maintained, as expected, its α-
configuration at C1 during the “click” reaction.  
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Figure 3.9 1H-NMR spectrum (300 MHz, CD3OD) of the acetylated glycocluster compound 5. 
 
The subsequent deprotection of the peracetylated Man-calix[4]arene 5 was carried out at 
room temperature by adding a freshly prepared sodium methoxide solution in methanol 
according to the standard Zemplén procedure25. Complete removal of the acetyl groups 
could be achieved in 3 hours as determined by ESI-MS analyses: the peak at m/z 1560.3 
corresponding to the [M+Na]+ species unambiguously confirmed that the desired 
compound 6 was obtained. Product 6 was completely characterized with NMR techniques. 
1H NMR spectrum of 6 (fig. 3.10) shows the disappearance of the methyl singlets of the 
acetyl groups between 2.10-1.60 ppm and the presence of different conformation for this 
compound.  
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Figure 3.10 1H-NMR spectrum (300 MHz, DMSO-d6, 70 °C) of the acetylated glycocluster compound 6. 
 
From the NMR spectra we observed the presence of different signals for the proton of the 
ureidic NH protons close to the sugars, for the H1 of the sugar moieties and also for the 
aromatic protons. Such behaviour is quite common in ureido glycosides although was not 
frequently observed previously in glycosylcalixarenes. This seems to be due to the fact that 
thiourea linkers have different possible configurations (ZZ, ZE, EZ or EE)20 that are in 
equilibrium between each other and are possibly stabilized by intramolecular hydrogen 
bonding. These equilibria usually influence the 1H-NMR spectra only in non polar solvent 
and at room temperature; in this case of compound 6, however, high temperatures and 
changes to more polar solvents (T =  70° C, DMSO-d6) seem not to significantly change the 
1H-NMR profiles. It is feasible, therefore, that this anomalous splitting of protons might 
originate from the particular stereochemistry of α-mannosylthioreido groups which 
present both the 1,2 bulky substituents (the OH group and, expecially, the 
thioureidocalixarene) in axial positions on both C1 and C2 and that might affect the 
pyranosyl conformation (vide infra for a comparison with the conformation of monomers 
12 and 14). This hypothesis is confirmed from a COSY experiment where it is possible to 
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see a correlation between the aromatic peaks and the H1 signals of the different 
configurations that, in turn, correlate with only one H2.  
Another confirmation to the hypothesis of the presence of different conformations for 
compound 6, and thus indicating that the compound is pure, comes from the ESI-MS 
analysis where the main peak present is that of the sodiated molecular ion at m/z 1560.4. 
 
 
3.2.2 Synthesis of the monomers 
 
In order to compare the behaviour of the glycocalixarene structure with those of acyclic 
monovalent systems, we also decided to synthesize two different and simpler glycosides, 
constituted by a single aromatic nuclei bearing only one saccharide unit and thus 
resembling the monomeric homologue of the compound 6. The first one is a propyl ether 
derivative (12) exactly as glycocalix 6, while the second one (14) bears a longer lipophilic 
hexyl chain, to increase the liphophilic character of the amphiphile system.  This should 
help the adhesion of the monomer onto the AuNPs and the stability of the resulting water 
soluble particles.  
The synthesis of the two monomers was carried out in a way similar to that of the 
calixarene (fig. 3.11). We started from the commercially available para-nitrophenol that 
was alkylated on the hydroxyl group using propyl iodide or hexyl bromide and K2CO3 in 
refluxing acetonitrile. This reaction lead to the desired products (7 and 9) without any 
further purification and in quantitative yields. The nitro groups were subsequently 
reduced to amino groups using hydrazine and Pd/C (10%) in ethanol. Also in these cases 
no purification step was needed and the yield was very high (90-95%). The complete 
reduction is confirmed by 1H-NMR spectra that show the appearance of the broad singlet 
of the NH2 between 3.40 and 3.50 ppm and the shift and the superimposition of the 
aromatic proton signals at higher field.  
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Figure 3.11 Synthesis of the amino intermediates 8 and 10 of the monomeric analogues 12 and 14. 
 
The conjugation of α-mannosyl isothiocyanate was carried out similarly to that on the 
calixarene scaffold (fig. 3.12), using a click reaction to link the phenolic ring to the sugar 
moiety and thus obtaining a thiourea spacer. Also in this case the reaction gave the 
mannosyl conjugates (11 or 13) without significant by-products and only a simple 
purification step was necessary to remove the excess of mannosyl isothiocyanate. The 
presence of the desired products was confirmed from the signals of the thiourea NH over 
8.5 ppm in 1H-NMR spectra.  
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Figure 3.12 Synthesis of monomeric analogues 12 and 14 of mannosylcalixarene 6. 
 
The subsequent step was the deprotection of the peracetylated compounds (11 and 13) to 
give products 12 and 14. The methanolysis of the acetate groups was carried out at room 
temperature by adding a freshly prepared sodium methoxide solution in methanol to 
compound 11 or 1322. Complete removal of the acetyl groups could be achieved in 3 hours 
and was followed via ESI-MS analyses. 
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As in the case of compound 6, the 1H-NMR spectra of monomers show splitting of some of 
the signals. In these cases, due to the simplicity of the structure, it is more simple to 
evidence the presence of two different sets of signals, that do not interconvert one into the 
other even in polar solvent or at high temperature. These two sets of signals are more 
evident in the protected compounds (11 or 13), where two different signals for NH 
protons, H1, H3 and H6 are clearly evident (figure 3.13). Also in this case COSY 
experiment and ESI-MS spectra helped to confirm the hypothesis that in any case we are 
in presence of the single desired compounds 11 and 13. Contrary to what observed in 
calixarene 9, however, the 1 HNMR spectra of the deprotected compounds 12 and 14 (fig 
3.14) have only a simple set of signals that is indicative of a system with only a single 
species present.  
 
  
a) 
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Figure 3.13 1H-NMR (400MHz, DMSO-d6) spectra: a) CD3OD, 13; b) CD3OD/D2O = 9/1, 17. 
 
 
b) 
a) 
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Figure 3.14 1H-NMR (400MHz) spectra: a) CD3OD, 14; b) CD3OD/D2O = 9/1, 18. 
 
 
3.2.3 Synthesis and functionalization of gold nanoparticles§ 
 
Colloidal solutions of metals have been known for a long time and a large variety of 
preparative techniques is now available. Depending on the preparative conditions, the 
particles have a tendency to agglomerate slowly, eventually lose their disperse character 
and flocculate. The removal of the solvent generally leads to the complete loss of the 
ability to reform a colloidal solution. Preparation of colloidal metals in a two-phase system 
was introduced by Faraday26, who reduced an aqueous gold salt with phosphorus in 
carbon disulfide and obtained a ruby red coloured aqueous solution of dispersed gold 
particles. Combining this two-phase approach with more recent techniques a new 
synthetic strategy comes up. 27,288  
The strategy followed consisted in growing the metallic clusters with the simultaneous 
attachment of self-assembled thiol monolayers on the growing nuclei. In order to allow the 
surface reaction to take place during metal nucleation and growth, the particles were 
                                                 
§
 This part of the work is carried out with the collaboration of the group of Prof. Davide Prosperi, Università Bicocca, 
MI 
b) 
Chapter 3 
77 
grown in a two-phase system. Two-phase redox reactions can be carried out by an 
appropriate choice of redox reagents present in the two phases. In the present case, AuCl4- 
was transferred from the aqueous solution to toluene using tetraoctylammonium bromide 
as the phase-transfer reagent and reduced with aqueous sodium borohydride, followed by 
functionalization with dodecanethiol (C12H25SH) (Brust – Schiffrin Method).28 These types 
of AuNPs are “soluble” and stable only in organic non polar solvents (fig 3.15). This  fact 
limits consistently the applicability of these materials for most of biological applications, 
where the most important characteristic is water-solubility.  
 
 
Figure 3.15 TEM image of AuNPs 
 
So in order to obtain new nanoparticles that can be used for bio-recognition, bio-imaging 
and targeted drug delivery it is necessary to have water-soluble AuNPs. To achieve this 
purpose there are, in literature, many methodologies describing functionalization of 
AuNPs, but almost all of them are based on a covalent modification of the Au surface of 
nanoparticles mainly with thiols and thioesters. 
In our case, we decided to explore a new methodology and to functionalize AuNPs using 
non-covalent interactions, specifically hydrophobic effects between the lipophilic part of 
glycocalixarene and the long alkyl chains on NPs surface. Following such strategy, we 
planned therefore to exploit the lipophilic properties of the dodecanthiol outer layer of  
AuNPs to possibly fix glycocalixarenes on the nanoparticles. This should ensure the 
exposure of the glycosyl units on the outer NP layers making them water soluble and 
potentially efficient multivalent ligands for the interaction with proteins (lectins) that are 
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present on cellular surface or over-expressed in tumor cells. For this purpose we decided 
to limit this studies to the sugar moieties of mannose and galactose on calixarenes 6 and 
15, respectively (fig. 3.16). 
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Figure 3.16 Glycocalixarene used for AuNPs funtionalization. 
 
In order to compare the real role of the calixarene scaffold in both stabilizing AuNPs and 
in the interaction efficiency/selectivity with appropriate cell lines we decided also to try to 
functionalize AuNPs with monovalent compounds (monomers) 12 and 14 that represent 
the monovalent acyclic analogs of the mannose calix[4]arene 6 used (fig. 3.17). 
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Figure 3.17 Monovalent compounds. 
 
All the glycosyl-functionalized AuNPs were prepared using the same procedure: the 
glycocalixarene or monomer dissolved in methanol is added to a suspension of AuNPs in 
chloroform. The mixture was allowed to interact for a few minutes, afterwards the 
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solvents were evaporated giving a red-colored thin film of nanoparticles. At this point 
sodium borate buffer (SBB: pH 12) was added and sonicated for a few minutes resulting in 
stable water soluble nanoparticles. As prepared NPs were washed by repeated 
centrifugation and re-dispersion in SBB. The final concentration of the AuNPs was 
calculated from the UV-VIS spectrum using extinction coefficient of 3.07×107 M-1cm-1. All 
the particles covered with calixarene result to be stable in water for a long time (1 month at 
least).  
A quite different behaviour was found for the two monovalent compounds, monomers 12 
and 14, using very similar procedure. Only for 14, in fact, it was possible to obtain stable 
water-soluble particles.  In this latter case a 4-fold excess of monomer was used compared 
to the cases of calixarene 6 and 15 in order to roughly keep the same ratio between sugar 
moieties and AuNPs. In case of monomer 12, on the other hand, it was impossible to 
dissolve the particles in water in none of the concentrations tried, probably because the 
lipophilic tail of the monomer (propyl chain) was too short to give rise to a stable 
interaction with the aliphatic NP surface. 
 
Au@Glycoside AuNPs (mol) Glyconjugate (mol) Sugar/AuNPs Molar ratio 
Au@6 4.41×10-9 6.26×10-6 5680/1 
Au@15 1.93×10-9 6.00×10-6 6216/1 
Au@14 4.03×10-9 24×10-6 5955/1 
Table 3.1 Mole and molar ratios of gold NPs and glycosylated compounds used in each of the 
functionalization steps. 
 
All stable particles were characterized using UV-Vis, DLS and Z-potential. In the UV-Vis 
spectra it was possible to identify the absorbance band of the calixarene compounds (220-
300 nm) and the plasmonic band of gold at around 520 nm. The band of gold is much less 
intense than expected and  this might be attributed to the high concentration of calixarene 
bonded on the NP surface, that gives rise to a very high UV-Vis absorbance between 220 
and 300 nm (fig. 3.18).  
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Figure 3.18 Examples of UV-Vis spectra. 
 
From the DLS measurements and the polydispersion index (PDI) it is also possible to 
understand that the particles are well monodispersed. The Z-potential values measured 
are quite negative (lower than -30) and this is a further confirmation of the stability of the 
functionalized AuNPs (table 3.2). 
 
Au@Glycoside DLS (nm) Z-potential (mV) UV-vis 
(nm) 
Au@6 47.2 (PDI 0.268) -41.31±1.79 522 
Au@15 53.2 (PDI 0.228) -40.59±2.71 522 
Au@14 59.4 (PDI 0.223) -37.65±1.94 527 
Table 3.2 DLS and Z-potential of the studied NPs. 
 
 
3.2.4 Preliminary uptake studies of glycosiylated Au nanoparticles** 
In a preliminary experiment, the glycosylated AuNPs (50 nM) were incubated for 2 h at 
37°C with HeLa cells that are known to have specific receptors for mannose and galactose. 
29 Cells were subsequently washed five times with PBS in order to remove the excess of 
unbound gold nanoparticles. Cells were also manually counted, for each sample, using a 
hemacytometer. In order to quantify the amount of gold present in the cells, 5 mL of aqua 
regia was added and the mixture was left for 72 h,  leading to the complete dissolution of 
                                                 
**
 This part of the work is carried out with the collaboration of the group of Prof. Davide Prosperi, Università Bicocca, 
MI 
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all the organic material. The samples were diluted with water to a final volume of 16 mL 
and the amount of gold was determined by ICP-AES (table 3.3).  
 
Sample code NPs concentration, nM Number of NP per cell 
Au@6 50 nM 13.5 x106 
Au@15 50 nM 36.8x106 
Au@14 50 nM 2.0 x106 
Table 3.3 Determination of gold contents in HeLa cells. 
 
The data obtained indicate a clear dependence of the AuNP uptake from the type of 
glycoside present on the outer NP layer. Quite interestingly, the AuNPs fuctionalized with 
glycocalixarenes are much better uptaken than Au@14 even if, also in this case, one should 
assume that the layer covering the NP is characterized by a multivalent presentation of 
carbohydrates. The presentation of mannoside units on a nultivalent scaffold such as 
calixarene 6 ensure a nearly 7 times higher uptake of Au@6 NP from the cells than in the 
case of the monovalent functionalized NPs Au@14. Moreover, galactoside functionalized 
Au@15 are bound by cells nearly three- and twenty-times better than mannoside 
functionalized NP Au@6 and Au@14, respectively. Therefore, even if preliminary, these 
data show a glycoside-dependent uptake of NPs by HeLa cells and, even more 
interestingly, that the presentation of the glycosides on a calixarene scaffold does give a 
significant advantage in terms of efficiency of binding of AuNPS to the cells. 
 
 
3.3 Conclusion 
 
Water-soluble gold nanoparticles functionalized with glycocalixarenes and with a 
phenylglycoside, taken as monomeric counterpart of these macrocycles, were obtained 
using a new non-covalent approach, that takes advantage of hydrophobic effects between 
the surface of the NPs and the lipophilic part of the glycosylated compounds. These new 
AuNPs were studied using UV-Vis spectroscopy and DLS evidencing a high stability in 
aqueous solutions even for long times. This methods represents therefore a novel and easy 
way to fuctionalize AuNPs with calixarene coatings and ensuring a fairly good solubility 
in aqueous solutions of these important materials for nanotechnology applications in 
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water. Preliminary studies of interaction of these glycosylated AuNPs with HeLa cells 
were carried out, and the amount of AuNP per cell was evaluated using ICS-AES 
technique. From these data it is possible to evidence a clearly different uptake of the three 
different AuNPs by the cells. Both the type of sugar present and the multivalent 
presentation of sugars on the NP seems to influence the uptake. Mannoside functionalised 
NPs (Au@14 and Au@6) are uptaken to a lower extent than galactoside functionalised 
Au@15 NPs. Quite interestingly, the presentation of the glycosides on calixarene scaffolds 
gives significant advantages in terms of efficiency of binding of AuNPS to the cells. 
 
 
3.4 Experimental Part 
 
General Information. All moisture sensitive reactions were carried out under nitrogen 
atmosphere, using previously oven-dried glassware. Dry solvents were prepared 
according to standard procedures, distilled before use and stored over 3 or 4 Å molecular 
sieves. Most of the solvents and reagents were obtained from commercial sources and 
used without further purification. Analytical TLC were performed using prepared plates 
of silica gel (Merck 60 F-254 on aluminum) and then, according to the functional groups 
present on the molecules, revealed with UV light or using staining reagents: H2SO4 (5% in 
EtOH), basic solution of KMnO4 (0.75% in H2O). Merck silica gel 60 (70-230 mesh) was 
used for flash chromatography and for preparative TLC plates. 1H NMR and 13C spectra 
were recorded on Bruker AV300 and Bruker AV400 spectrometers (observation of 1H 
nucleus at 300 MHz and 400 MHz respectively, and of 13C nucleus at 75 MHz and 100 
MHz respectively). All chemical shifts are reported in part per million (ppm) using the 
residual peak of the deuterated solvent, whose values are referred to tetramethylsilane 
(TMS, δTMS = 0), as internal standard. All 13C NMR spectra were performed with proton 
decoupling. Electrospray ionization (ESI) mass analyses were performed with a Waters 
spectrometer. Melting points were determined on an Electrothermal apparatus in closed 
capillaries. Microwave reactions were performed using a CEM Discovery System reactor.  
Compounds 15 and 16 was synthesized according to literature procedure, respectively ref. 
20 and 19. 
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Nomenclature of calix[4]arene compounds. 
In this thesis the simplified nomenclature proposed by Gutsche is used to name the 
calix[4]arene compounds. The positions on the macrocycle are numbered as indicated in 
the following figure. The hydroxyl substituent defines the ipso position: subsequently the 
ortho, meta and para positions on the aromatic rings are identified without ambiguity. 
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2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl bromide 2 
In a round bottom flask D-mannose (1.0 g, 5.6 mmol) was dissolved in acetic anhydride (5 
mL, 55 mmol) and then 3mL of hydrogen bromide until the sugar is completely dissolved, 
the other 3 mL (6 mL, 144 mmol). The mixture was stirred at room temperature for 8 h and 
checked via TLC (eluent: AcOEt/hexane 4:6). When completed, the solvent was removed 
under reduced pressure to give a brownish syrup, that was dissolved in toluene (three 
times) and then in Et2O (one time) and the solvent always removed. The crude syrup is 
purified via flash column chromatography (eluent hexane/AcOEt 6:4) to give the product 
ad a yellowish syrup with 51% yield. 1H-NMR (300 MHz, CDCl3): δ(ppm) 6.23 (d, J = 1.4 
Hz,1H, H1), 5.63 (dd, J = 3.3, 10.2Hz, 1H, H3), 5.36 (dd, J = 1.4, 3.3 Hz, H2), 5.29 (t, J = 9.9 
Hz, H4), 4.26 (dd, J = 4.8, 12.3 Hz, 1H, H6), 4.17 – 4.12 (m, 1H, H5), 4.06 (dd, J = 2.1, 12.3 
Hz, 1H, H6’), 2.10, 2.03, 2.00, 1.93 (4s, 12H, CH3). The product shows the same physical-
chemical properties reported in the literature. 8 
 
2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl isothiocyanate 3 
In a round bottom flask under nitrogen KSCN (0.150 g, 1.57 mmol), tBu4NI (0.285 g, 0.77 
mmol) were dissolved in CH3CN (10 mL) and stirred for 3h with 4Ǻ molecular sieves. 
Then the sugar 2 (0.318 g, 0.77 mmol) dissolved in CH3CN (3 mL) is added dropwise. The 
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reaction is refluxed for 24h and monitored with TLC (eluent hexane/AcOEt 6:4). The 
solution is cooled to room temperature and filtered. The solvent is removed by rotary 
evaporation and the crude is purified by flash column chromatography (eluent 
hexane/AcOEt 6:4). The product is obtained as a yellowish oil in a 63% yield. 1H-NMR 
(300 MHz, CDCl3): δ(ppm) 5.52 (d, J = 1.8 Hz, 1H, H1), 5.31 – 5.20 (m, 3H, H3, H2, H4), 4.24 
(dd, J = 5.1, 12.5 Hz, 1H, H6), 4.12 – 4.04 (m, 2H, H5, H6’), 2.12, 2.05, 2.01, 1.96 (4s, 12H, 
CH3). The product shows the same physical-chemical properties reported in the literature. 
9 
 
Cone-5,11,17,23-tetrakis[2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl-thioureido]-25,26,27, 
28-tetrapropoxycalix[4]arene 5 
Isothiocyanate derivative 3 (50 mg, 0.08 mmol) was added to a solution of amino-
calix[4]arene 420 (149 mg, 0.38 mmol) in 5 mL of dry CH2Cl2. Et3N (42 µL, 0.30 mmol) was 
also added and then the mixture was stirred at room temperature over night under N2 
atmosphere. The reaction progression was checked via TLC (eluent: 
AcOEt/hexane/CH3OH 5:5:1). The solvent was then removed under vacuum and the 
residue purified via column chromatography (eluent: AcOEt/hexane/CH3OH 5:5:1) to 
give product 5 as a light yellow solid. Yield: 65%. 1H NMR (300 MHz, CD3OD): δ (ppm) 
6.85 (bs, 8H, ArH), 6.75 (bs, 8H, NH), 6.06 (bs, 4H, H1), 5.39 – 5.32 (m, 8H, H2, H3), 5.23 (t, 
J = 8.7 Hz, 4H, H4), 4.47 (d, J = 13.2 Hz, 4H, ArCH2Ar), 4.36 (dd, J = 5.4, 12.2 Hz, 4H, H6), 
4.16 – 4.13 (m, 4H, H6’), 4.09 – 3.95 (m, 4H, H5), 3.89 (t, J = 7.3 Hz, 8H, OCH2CH2CH3), 3.24 
(d, J = 13.2 Hz, 4H, ArCH2Ar) 2.17, 2.08, 2.05, 2.02 (4s, 48H, COCH3), 1.96 (q, J = 7.3 Hz, 8H, 
OCH2CH2CH3), 1.05 (t, J = 7.3 Hz, 12H, OCH2CH2CH3). 13C NMR (75 MHz, CD3OD): 182.6 
(CS), 171.9, 171.2, 170.2, 170.0 (CO), 154.7 (Ar), 135.4 (Ar), 133.2 (Ar), 124.6 (Ar), 79.7 (C4), 
76.7 (OCH2), 70.4 (C5), 69.1 (C2), 68.9 (C3), 66.5 (C4), 62.0 (C6), 30.3 (ArCH2Ar), 23.1 
(OCH2CH2), 19.4, 19.2, 19.1 (COCH3), 9.4 (CH2CH3). ESI-MS: m/z 1128.2 (M+2Na)2+. 
  
Cone-5,11,17,23-tetrakis[α-D-mannopyranosyl-thioureido]-25,26,27,28-tetrapropoxy 
calix[4]arene 6 
In a round bottom flask compound 5 (102 mg, 0.046 mmol) was dissolved in MeOD. Some 
drops of a solution 1M of MeONa were added until pH 9. The reaction was stirred for 3h 
at room temperature and was monitored with TLC (eluent AcOEt/MeOH/H2O 5:2:1). 
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Amberlite resin IR 120/H+ was subsequently added for quenching. After neutralization, 
the resin was filtered off and the solvent removed from the filtrate under vacuum to give 
pure product in a quantitative yield. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 9.46 – 9.16 
(m, 8H, NH), 7.03 – 6.63 (m, 8H, Ar), 5.79 – 5.55  (m, 4H, H1), 4.86 – 4.50 (m, 12H), 4.37 (d, J 
= 12.9 Hz, 4H, ArCH2Ar), 4.27 – 4.19 (m, 4H), 3.84 (t, J = 6.6 Hz, 8H, OCH2CH2CH3), 3.70 – 
3.38 (m, 8H), under solvent peak (4H, ArCH2Ar), 1.92 (q, J = 6.6 Hz, 8H, OCH2CH2CH3), 
0.99 (t, J = 6.6 Hz, 12H, OCH2CH2CH3). 13C NMR (400 MHz, DMSO-d6): δ (ppm) 181.1 
(CS), 153.6 (Ar), 134.8 (Ar), 129.3 (Ar), 123.9 (Ar), 81.8, 79.1, 77.1, 74.8, 70.3, 66.9, 61.4, 30.7 
(ArCH2Ar), 23.2 (OCH2CH2), 10.6 (CH3).. ESI-MS: m/z 1560.4 (M+Na)+. 
 
1-Nitro-4-propoxybenzene 7 
In a round bottom flask under N2 4-nitrophenol (300 mg, 2.2 mmol) and K2CO3 (600 mg, 
4.3 mmol) were dissolved in 30 mL CH3CN dry. Then iodopropane (420 µL, 4.3 mmol) was 
added and the reaction is vigorously stirred and refluxed for 24h. The reaction was 
checked with TLC (eluent: hexane/AcOEt 1:1). The hot solution is filtered and the solvent 
is removed under reduced pressure. The compound is dissolved in CH2Cl2 and filtered 
again. The solvent is evaporated giving the pure compound as a yellow oil in a 97% yield. 
1H NMR (400 MHz, CDCl3): δ (ppm) 8.18 (d, J = 7.2 Hz, 2H, Ar), 6.93 (d, J= 7.2 Hz, 2H, Ar), 
4.00 (t, J = 6.4 Hz, 2H, OCH2CH2CH3), 1.84 (q, J = 6.4 Hz, 2H, OCH2CH2CH3), 1.05 (t, J = 6.4 
Hz, 3H, OCH2CH2CH3). The product shows the same physical-chemical properties 
reported in the literature.30 
 
1-Amino-4-propoxybenzene 8 
In a round bottom flask compound 7 (375 mg, 2.06 mmol) was dissolved in 15 mL EtOH 
and hydrazine hydrate (2 mL, 41 mmol) was added together with a catalytic amount of 
Pd/C. The reaction was stirred and refluxed for 24h. The solution was filtered and the 
solvent was removed under reduced pressure the pure product as a colorless oil in a 99% 
yield. 1H NMR (300 MHz, CDCl3): δ (ppm) 6.76 (d, J = 9.0 Hz, 2H, Ar), 6.62 (d, J= 9.0 Hz, 
2H, Ar), 3.85 (t, J = 7.0 Hz, 2H, OCH2CH2CH3), 3.42 (bs, 2H, NH2), 1.78 (q, J = 7.0 Hz, 2H, 
OCH2CH2CH3), 1.04 (t, J = 7.0 Hz, 3H, OCH2CH2CH3). The product shows the same 
physical-chemical properties reported in the literature.12 
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1-Hexyloxy-4 nitrobenzene 9 
In a round bottom flask under nitrogen 4-nitrophenol (300 mg, 2.2 mmol) and K2CO3 (600 
mg, 4.3 mmol) were dissolved in 30mL CH3CN dry. Then iodohexane (640µL, 4.3 mmol) 
was added and the reaction was vigorously stirred and refluxed for 24h. The reaction was 
checked with TLC (eluent: hexane/AcOEt 1:1). The hot solution was filtered and the 
solvent was removed under reduced pressure. The compound was dissolved in CH2Cl2 
and filtered again. The solvent was evaporated giving the pure compound as a yellow oil 
in a 98% yield. 1H NMR (300 MHz, CDCl3): δ (ppm) 8.09 (d, J = 9.3 Hz, 2H, Ar), 6.87 (d, J= 
9.3 Hz, 2H, Ar), 3.97 (t, J = 6.3 Hz, 2H, OCH2), 3.49 (bs, 2H, NH2), 1.73 (q, J = 6.3 Hz, 2H, 
OCH2CH2), 1.43 – 1.25 (m, 6H, CH2), 0.85 (t, J = 6.3 Hz, CH3). The product shows the same 
physical-chemical properties reported in the literature.31 
 
1-Hexyloxy-4 aminobenzene 10 
In a round bottom flask compound 9 (506 mg, 2.3 mmol) was dissolved in 30 mL EtOH 
and hydrazine hydrate (2.2 mL, 45 mmol) was added together with a catalytic amount of 
Pd/C. The reaction was stirred and refluxed for 24h. The solution was filtered and the 
solvent was removed under reduced pressure the pure product as a in a 86% yield. 1H 
NMR (300 MHz, CDCl3): δ (ppm) 6.69 – 6.61 (m, 4H, Ar), 3.80 (t, J = 6.6 Hz, 2H, OCH2), 
1.65 (q, J = 6.6 Hz, 2H, OCH2CH2), 1.37 – 1.17 (m, 6H, CH2), 0.81 (t, J = 6.6 Hz, 3H, CH3). 
The product shows the same physical-chemical properties reported in the literature.13 
 
4-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl-thioureido)-1-propoxybenzene 11 
Isothiocyanate derivative 3 (580 mg, 1.0 mmol) was added to a solution of 8 (150 mg, 1.5 
mmol) in 20 mL of dry CH2Cl2. Et3N (200 µL, 1.5 mmol) was also added and then the 
mixture was stirred at room temperature over night under N2 atmosphere. The reaction  
was checked via TLC (eluent: AcOEt/hexane 4:6). The solvent was then removed under 
vacuum and the residue purified via column chromatography (eluent: AcOEt/hexane ) to 
give product 11 as a light yellow solid. Yield: 93%. 1H NMR (400 MHz, DMSO-d6): δ 
(ppm) 9.59 (s, 0.3H, NH), 9.45 (s, 0.7H, NH), 8.83 (d, J = 8.8Hz, 1H, NH), 7.34 (d, J = 8.8 Hz, 
2H, ArH), 6.99 (d, J = 8.8 Hz, 2H, ArH), 6.15 (d, J = 6.8 Hz, 0.3H, H1), 6.05 (d, J = 6.8 Hz, 
0.7H, H1), 5.42 (dd, J = 3.6, 9.4 Hz, 1H, H3), 5.17 - 5.04 (m, 2H, H2, H4), 4.20 (dd, J = 5.2, 
12.2 Hz, 1H, H6), 4.06 – 3.97 (m, 2H, H6’, H5), 3.91 (t, J = 7.0 Hz, 2H, OCH2CH2CH3), 2.14, 
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2.03, 2.01, 1.98 (4s, 12H, OCH3), 1.71 (q, J = 7.0 Hz, 2H, OCH2CH2CH3), 0.97 (t, J = 7.0 Hz, 
3H, OCH2CH2CH3). 13C NMR (100 MHz, CD3OD): δ (ppm) 182.9 (CS), 171.0, 170.1, 170.0, 
169.9 (CO), 157.5, 157.4 (Ar), 126.4 (Ar), 126.3 (ArH), 114.2 (ArH), 79.4 (C1), 69.4 (C2), 69.9 
(OCH2CH2CH3), 68.8 (C3), 66.6 (C4), 62.0 (C5), 61.9 (C6), 22.2 (OCH2CH2CH3), 19.2 
(COCH3), 9.4 (OCH2CH2CH3). ESI-MS: m/z 563.1 (M+Na)+, 1103.3 ([M-M]+Na)+. 
 
4-α-D-mannopyranosyl-thioureido-1-propoxybenzene 12 
In a round bottom flask compound 11 (458 mg, 0.85 mmol) was dissolved in MeOD. Some 
drops of a solution 1M of MeONa were added until pH 9. The reaction was stirred for 3h 
at room temperature and was monitored with TLC (eluent AcOEt/MeOH/H2O 5:2:1). 
Amberlite resin IR 120/H+ was subsequently added for quenching. After neutralization, 
the resin was filtered off and the solvent removed from the filtrate under vacuum to give 
pure product in a quantitative yield. 1H NMR (400 MHz, CD3OD): δ (ppm) 7.29 (d, J = 8.8 
Hz, 1H, ArH), 7.23 (d, J = 8.8 Hz, 1H, ArH), 6.94 (d, J = 8.8 Hz, 1H, ArH), 6.90 (d, J = 8.8 
Hz, 1H, ArH), 5.69 (bs, 1H, H1), 3.93 (t, J = 6.8 Hz, 2H, OCH2CH2CH3), 3.87 – 3.81 (m, 2H, 
H6, H2), 3.70 – 3.61 (m, 2H, H6’), 3.52 – 3.49 (m, 2H, H5, H3), under solventi peak (H4), 
1.79 (q, J = 6.8 Hz, OCH2CH2CH3), 1.04 (t, J = 6.8 Hz, OCH2CH2CH3). 13C NMR (100 MHz, 
CD3OD): δ (ppm) 181.1 (CS), 156.8, 157.2 (Ar), 126.6 (ArH), 114.9 (ArH), 82.0 (C1), 78.3 
(C4), 74.3 (C3), 70.7 (C2), 69.4 (OCH2CH2CH3), 66.7 (C5), 61.5 (C6), 22.2 (OCH2CH2CH3), 9.4 
(OCH2CH2CH3). ESI-MS: m/z 395.1 (M+Na)+, 767.4 ([M-M]+Na)+. 
 
4-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl-thioureido)-1-hexyloxybenzene 13 
Isothiocyanate derivative 3 (450 mg, 1.1 mmol) was added to a solution of 10 (150 mg, 0.77 
mmol) in 15 mL of dry CH2Cl2. Et3N (160 µL, 1.1 mmol) was also added and then the 
mixture was stirred at room temperature over night under nitrogen atmosphere. Reaction 
checked via TLC (eluent: AcOEt/hexane 3:7). The solvent was then removed under 
vacuum and the residue purified via column chromatography (eluent: AcOEt/hexane ) to 
give product 13 as a light yellow solid. Yield: 90%. 1H NMR (300 MHz, DMSO-d6): δ 
(ppm) 10.40 (d, J = 9 Hz, 0.3H, NH), 9.44 (s, 1H, NH), 8.83 (d, J = 9 Hz, 0.7H, NH), 7.32 (d, J 
= 9 Hz, 2H, ArH), 6.87 (d, J = 9 Hz, 2H, ArH), 6.03 (d, J = 6.9 Hz, 0.7H, H1), 5.85 (d, J = 6.9 
Hz, 0.3H, H1), 5.40 (dd, J = 3.6, 9.3 Hz, 1H, H3), 5.15 – 5.07 (m, 2H, H2, H4), 4.22 – 4.16 (m, 
1H, H6), 4.03 – 3.90 (m, 4H, H6’, H5, OCH2CH2), 2.02, 1.99, 1.98, 1.97 (4s, 12H, OCH3), 1.67 
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(m, 2H, OCH2CH2), 1.38 – 1.29 (m, 6H, CH2), 0.95 – 0.80 (m, 3H, CH3). 13C NMR (100 MHz, 
DMSO-d6): δ (ppm) 182.1 (C=S), 170.5, 170.4, 169.9, 169.8 (C=O), 156.5 (Ar), 132.1 (Ar), 
126.0 (ArH), 114.6 (ArH), 79.6 (C1), 69.6 (C3), 68.8 (C2), 68.0 (OCH2), 66.6 (C4), 62.5 (C6), 
62.3 (C5), 31.4, 29.1, 25.6, 22.5 (CH2), 14.4 (CH3). ESI-MS: m/z 605.3 (M+Na)+, 1187.7 ([M-
M]+Na)+. 
 
4-α-D-Mannopyranosyl-thioureido-1-hexyloxybenzene 14 
In a round bottom flask compound 13 (140 mg, 0.24 mmol) was dissolved in MeOH. Some 
drops of a solution 1M of MeONa were added until pH 9. The reaction was stirred for 3h 
at room temperature and was monitored with TLC (eluent AcOEt/MeOH/H2O 5:2:1). 
Amberlite resin IR 120/H+ was subsequently added for quenching. After neutralization, 
the resin was filtered off and the solvent removed from the filtrate under vacuum to give 
pure product in a quantitative yield. 1H NMR (400 MHz, CD3OD): δ (ppm) 7.26 (m, 2H, 
ArH), 6.91 (m, 2H, ArH), 5.86 (bs, 0.3H, H1), 5.69 (bs, 0.7H, H1), 3.97 (t, J = 6.2 Hz, 2H, 
OCH2CH2), 3.87 – 3.61 (m, 3H, H2, H6, H6’), 3.53 – 3.45 (m, 2H, H3, H5), under solvent 
peak (H4), 1.77 (q, J = 6.2 Hz, 2H, OCH2CH2), 1.49 – 1.22 (m, 6H, CH2), 0.93 (t, J = 6.2 Hz, 
3H, CH3). 13C NMR (100 MHz, CD3OD): δ (ppm) 181.0 (CS), 157.5, 156.8 (Ar), 126.5 (ArH), 
115.1 (ArH), 81.2 (C1), 78.3 (C4), 74.3 (C5), 70.9 (C2), 67.8 (OCH2), 61.5 (C6), 31.4, 28.9, 25.4, 
22.3 (CH2), 12.9 (CH3). ESI-MS: m/z 437.1 (M+Na)+, 851.4 ([M-M]+Na)+. 
 
Synthesis of Gold Nanoparticles (AuNPs) 
A solution of tetraoctylammonium bromide (2.17g, 3.97 mmol) toluene (80 mL) and a 
solution of hydrogen tetrachloroaurate (III) (0.30 g, 0.88 mmol) in mQ water (25 mL) were 
prepared. The two solution were placed in a separating funnel and stirred vigorously. The 
organic layer was separated and put in a round bottom flask and a solution of NaBH4 
(0.334 g, 8.8 mmol) in mQ water (25 mL) was added dropwise. The solution was stirred for 
an hour then washed with HCl 10 mM (25 mL), NaOH 10 mM (25 mL), water mQ (4x24 
mL). The organic solution was stirred overnight then 10mL of dodecanthiol was added 
and the solution was heated at 65° C for 3 hour. The cooled solution was centrifuged for 5 
min at 2000 rpm. Non-aggregated nanoparticles solution is separated from the 
precipitated nanoparticles and diluted with methanol and centrifuged for 5 min at 2000 
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rpm, re-disperding the final nanoparticles in chloroform.13 AuNPs concentration was 
calculated from UV-Vis spectrum using a calibration line and absorbance peak at 520 nm. 
 
AuNPs functionalization.  
Compounds 6 (cone–4Man–calix[4]arene), 15 (cone–4Gal-calix[4]arene), 16 (cone– 4GlcNAc -
calix[4]arene), 14 (4-Man-1-hexyloxybenzene) were used to transfer the AuNPs from 
organic to water phase.  
 
Au@6  NPs. 500 µL of 8.44 µM AuNPs were diluted with 50 mL of chloroform, followed by 
addition of 6 methanol solution (3.13 mL, 2 mM). The mixture was allowed to react for a 
few minutes, afterwards the solvents were evaporated giving a red-colored thin film of 
nanoparticles. 2-3 mL of SBB were added and sonicated for a few minutes resulting in 
stable water soluble nanoparticles. As-prepared NPs were washed by repeated 
centrifugation at 7000 rcf for 5 min and re-dispersion in SBB. The final concentration of the 
AuNPs was calculated from the UV-Vis spectrum using extinction coefficient of 3.07×107 
M-1cm-1 as described by Haiss et al.32  
 
Au@15 NPs. 500 µL of 8.44 µM AuNPs were diluted with 50 mL of chloroform, followed 
by addition of 15 methanol solution (3 mL, 2 mM). The mixture was allowed to react for a 
few minutes, afterwards the solvents were evaporated giving a red-colored thin film of 
nanoparticles. 2-3 mL of SBB were added and sonicated for a few minutes resulting in 
stable water soluble nanoparticles. As-prepared NPs were washed by repeated 
centrifugation at 7000 rcf for 5 min and re-dispersion in SBB. The final concentration of the 
AuNPs was calculated from the UV-Vis spectrum using extinction coefficient of 3.07×107 
M-1cm-1 as described by Haiss et al.31 
 
Au@14 NPs. 500 uL of 8.06 uM GNPs were diluted with 50 mL of chloroform, followed by 
addition of 14 methanol solution (1.2 mL, 20 mM). The mixture was allowed to react for a 
few minutes, afterwards the solvents were evaporated giving a red-colored thin film of 
nanoparticles. 2-3 mL of SBB were added and sonicated for a few minutes resulting in 
stable water soluble nanoparticles. As-prepared NPs were washed by repeated 
centrifugation at 7000 rcf for 5 min and re-dispersion in SBB. The final concentration of the 
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AuNPs was calculated from UV-vis spectrum using extinction coefficient of 3.07×107 M-
1cm-1 as described by Haiss et al.16  
 
Determination of Gold Content by ICP-AES. 
HeLa Cells were incubated for 2 h at 37°C with concentration of 50 nM Glycoside-
functionalized nanoparticles in 3 cm dishes and were subsequently washed five times with 
PBS in order to remove excess gold nanoparticles. In order to detach the cells from the 
dish, 1 mL of aqueous trypsin solution was added and the detached cells were rinsed out 
with 4 mL of medium, centrifuged and re-dispersed in 2 mL of PBS carefully avoiding any 
loss. To this suspension was added 5 mL of aqua regia and the mixture was left for 72 h,  
leading to the complete dissolution of all cellular material. The samples were diluted with 
water to a final volume of 16 mL before the intracellular amount of gold was determined. 
Cells were counted manually using a hemacytometer after trypsinization, for each sample.  
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4.1 Introduction♣ 
 
With the development of life science, the research on the intracellular active species, cell 
signal transduction and apoptosis has become more and more signiﬁcant in the ﬁeld of 
biomedical research and clinical diagnostics. Molecular imaging is playing an increasingly 
important role in this research. Fluorescent bioimaging, among all kinds of molecular 
imaging methods, provides a high spatial resolution, which is widely used for cell and 
tissue imaging in biomedical research and is an effective analytical technique to solve the 
problems that cannot be resolved by other conventional imaging methods. 1 
Therefore, ﬂuorescent bioimaging has become a very active research ﬁeld in recent years. 
Among various classes of ﬂuorophores, phosphorescent heavy-metal complexes possess 
excellent photophysical properties, as explained in chapter 1, such as evident Stokes shifts 
and relatively long emission lifetime (µs to ms). This long emission lifetimes permit to 
avoid the interference from short-lived autoﬂuorescence (background fluorescence) and 
scattered light by using a time-resolved imaging technique. Thus, it is anticipated that 
such a class of phosphorescent materials could be used as appealing candidates for 
bioimaging. Compared with other ﬂuorophores, however, limited examples have been 
reported about the application of phosphorescent heavy-metal complexes in bioimaging to 
date.2 
For application in bioimaging, the phosphorescent probes should be water-soluble 
because the interaction media is water or a buffered solution. However, the water-
solubility of most reported phosphorescent heavy-metal complexes for bioimaging is very 
poor, and the addition of organic solvents (such as DMSO) is often required in the imaging 
experiments to improve the solubility of heavy-metal complexes in the aqueous media. 
However, the addition of organic solvents in sufficient amounts to warrant solubility is 
usually toxic to cell life and/or destroy the cell membrane, thus limiting the real 
application of phosphorescent probes. Therefore, it is necessary to develop new 
phosphorescent probes endowed with a high or complete solubility in water. 3 
In this chapter the synthesis and characterization of luminescent Platinum (II) complexes 
functionalized with sugars on the ancillary ligand in order to make these complexes, 
                                                 
♣
 The synthesis and the photo-physical measurements  of the complexes  presented in this chapter were carried out 
during my three months stage period  the ISIS  of Strasbourg (France) under the supervision of Prof. Luisa De Cola. 
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usually liphophilic and soluble only in organic solvents, water soluble and to study their 
facilitated uptake by the cells, is described. These compounds could potentially be able to 
efficiently enter and selectively stain cells or particular compartments inside cell (such as 
cytoplasm, organelles or the nucleus) thanks to the interaction of the sugar units with 
lectins or other carbohydrate binding proteins.4 Moreover, such kind of complexes could 
also produce a supramolecular structures such as chiral fibres or aggregates that can 
enhance the emission intensity. 5 
 
 
4.2 Results and discussion 
 
Platinum (II) complexes have a planar-squared geometry, and those studied herein have a 
tridentate bis-(1,2,4-triazolyl)-pyridine chelating ligand, carrying CF3 groups on the free 3-
positions of the triazole rings. A monodentate ligand, usually called ancillary ligand, 
complete the coordination around the metal ion. The ancillary ligand is frequently a 
substituted pyridine, and is well-known that the photophysical properties of these 
complexes are mainly characterized by the tridentate ligand (fig. 4.1). Several of the tested 
complexes have been shown to be able to cross the cell membranes and localize in specific 
cell compartments, depending on their chemical structure. Due to the emitting 
characteristics of these complexes, mainly related to the change of the emission upon 
aggregation, it was also shown to be possible to follow their distribution and pathways 
within cells.  
 
 
Figure 4.1 Schematic representation of platinum(II) complexes. 
 
We planned therefore to functionalize these complexes with D-glucose, due to the 
relevance of such saccharide in the interaction with bio-medical important carbohydrate-
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binding proteins (lectins). This will possibly influence the uptake of the complex by the 
different cell-lines and modulate the formation of aggregates, by the different environment 
provided by the cell or by the proteins (lectins) where the complexes will be localized. D-
glucose is also one of the most hydrophilic pyranosidic monosaccharides and this should 
ensure a higher solubility in water of its conjugates. However, once demonstrated the 
proof-of-principle that conjugation of glycosides to these Pt-complexes enhances the 
efficiency and/or selectivity of uptake by the cells, it could be easily planned to insert 
other and more biologically relevant mono- or oligosaccharides. 
Of the different positions where the carbohydrate could be introduced, we choose the 
ancillary ligand (para position) for different reasons. First of all, since the photophysics of 
these complexes mainly depend from the tridentate bis-triazolyl-pyridine, we decided not 
to change this unit and to leave the -CF3 groups in 3-positions which ensure excellent 
emission properties. Second, the functionalization of the pyridine ancillary ligand should 
result much easier and simply by mixing the glycosylated pyridine with the Pt-bis-
triazolyl-pyridine would result in the formation of the final desired glycosylated Pt 
complexes. Finally, even if the single final Pt complexes bear only one carbohydrate unit, 
the known possibility to aggregate in fibers of these complexes5,6 might result in the 
formation of a polyglycosylated noncovalent assemblies potentially able to exploit a 
glycoside cluster effect in the recognition of lectins. 
 
 
4.2.1 Synthesis of the glycosylated ancillary ligands 
 
Two different pyridine-based sugar functionalized ancillary ligands were synthesized 
using the same sugar (D-glucose) but different way to link the sugar to the pyridine ring 
and different distance between the sugar and the pyridine (fig. 4.2).  
The different spacers were also chosen for the easy and straightforward way of 
conjugation and for their polarity that should also help the solubility in water. Quite 
different are the synthetic pathways to obtain compounds 8 and 12. A synthetic strategy 
consisting in a three-step, for the former, and two-step, for the latter, convergent approach 
before conjugation, was planned (fig. 4.3 and 4.4).  
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Figure 4.2 The two pyridine-based ancillary ligands. 
 
For obtaining the triazole linked 8, in fact, a CuAAC (Copper-catalyzed Azido-Alkyne 
Cycloaddiction) was used and, for this reason, an azido sugar and an alkyne pyridine 
were synthesized (fig. 4.3 and 4.4). The synthesis started with the functionalization of the 
glucose (fig. 4.3). The sugar was fist totally acetylated using acetic anhydride and sodium 
acetate obtaining the pentaacetate 2.7 Then using 2-bromo ethanol and boron trifluoride 
diethyl etherate as Lewis acid for the glycosylation, the anomeric position was 
functionalized obtaining, after purification, the compound 38 having a terminal 
bromoalkoxy group on the sugar C1 position.  Compound 4 is then obtained thanks to the 
reaction of 3 with sodium azide at 65 °C in dry DMF and high yield without any 
purification needed.  
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Figure 4.3 Synthesis of the azido sugar 4. 
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For what concerns the pyridine moiety (fig. 4.4) the synthesis started from the 
commercially available 4-iodo-pyridine. Carrying out a Sonogashira reaction with 
trimethylsilylacetylene as alkyne donator and diisopropylamine as base, compound 69 was 
obtained after column chromatography purification. At this point the alkyne moiety was 
deprotected using potassium hydroxide in methanol/dicloromethane obtaining the 4–
ethynylpyridine 7.5 This compound was then used, together with 4, in a CuAAC reaction, 
that generates the triazole nucleus as linker between the sugar and the pyridine. This 
reaction was carried out using copper (II) sulfate pentahydrate and sodium ascorbate in 
DMF/H2O, upon microwave irradiation (150W at 80 °C, t = 20 min.). Compound 8, the 
first of the two ancillary ligands, was obtained pure after column chromatography that is 
needed simply to remove the excess of sugar used; no other by-products were in any case 
detected. The successful outcome of this click reaction was confirmed from 1H-NMR 
spectroscopy where it is well visible the signal at 8.13 ppm of the CH of the triazole ring, 
together with all the signal of the sugar between 3.5 and 5.5 ppm and the two doublets of 
the pyridine ring at 8.72 and 7.97 ppm (fig. 4.5). The identity of compound 8 was also 
confirmed from ESI-MS where it is present the [M+Na]+ peak at 543 m/z. 
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Figure 4.4 Synthesis of the ethynylpyridine 7 and of the protected ancillary ligand 8 
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Figure 4.5 1H-NMR (400 MHz, CDCl3) of  8 
 
To obtain the amido linked ligand 12 the synthesis started from the commercially available 
α-D-bromo tetraacetylglucose (fig. 4.6) that thanks to an SN2 reaction on the anomeric 
position under phase transfer catalysis condition using sodium azide as nucleophile and 
tetrabutylammonium hydrogen sulfate, was transformed in the β-D-azido 
tetraacetylglucose 10. The success of the reaction was confirmed from 1H-NMR spectra, 
where the signal of the anomeric proton is shifted to higher fields (lower ppm), as 
expected from the change in its stereochemistry. Compound 10 was then reduced using H2 
and palladium on carbon, as catalyst, to give β-D-amino tetraacetylglucose 11. Also in this 
case 1H-NMR spectroscopy and ESI-MS spetrometry confirm the identity and purity of the 
product. At this point this sugar could be used for the condensation with commercially 
available isonicotinic acid to give product 12, the second ancillary ligand. The reaction was 
carried out in presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) in dry 
THF (5mL) for 12 hour. A proper integration between the signals of the aromatic protons 
and those of the sugar in the 1H-NMR spectra together  with  the presence of the signal of 
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the NH of the amido group at 7.55 ppm confirmed that conjugation properly took place 
and that the amino group was formed (fig. 4.7). 
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Figure 4.6 Synthesis of the ancillary ligand 12. 
 
 
Figure 4.7 1H-NMR (CDCl3, 400 MHz) of compound 12. 
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4.2.2 Synthesis of the platinum (II) complexes and their deprotection 
 
The synthesis of the complexes was carried out using well-known procedures in the group 
of Prof. De Cola at ISIS in Strasbourg during my period of stage abroad. The complex of 
Platinum used as a precursor was a dichloride bis-dimetysulfoxide complex and as the 
tridentate ligand we used a pyridine functionalized with two 1,2,4-triazole bearing a CF3 
group in 3-position. The choice of those N^N^N ligand was driven by the knowledge that 
this ligand was proved to give quite high emissive complexes, that in some cases tend to 
form supramolecular aggregates, such as fibres. This aggregation results to be important 
in terms of emission. In fact, it is experimentally proved that when those N^N^N 
Platinum complexes form fibers, or aggregates in general, the emission results to be 
improved and sometimes also red shifted, thanks to the Pt-Pt interaction.6 
The complexation reactions is always carried out using two subsequent steps: the first one 
in order to obtain the chelate complexes and the second one to introduce the ancillary 
ligand (fig. 4.8).  
For the first step Platinum complex precursor was dissolved under nitrogen in CHCl3 with 
the tridentate ligand, and a non-coordinating and non-nucleofilic base, such as DIPEA or 
K2HPO4, was added. The reaction was stirred until the formation of the complex is evident 
from turning the solution to yellowish. At this point the ancillary ligand can be added to 
the solution that was then heated at 60 °C. The complex was formed after one night 
reaction and purification was carried out by column chromatography. While complex 14 is 
well soluble in CHCl3 and CH2Cl2, complex 13 is only slightly soluble in most organic 
solvent, but is well soluble in hexafluoroisopropanol.  
To characterize ad confirm the presence of these compounds both NMR (1H and 19F) and 
ESI-MS were used. In both cases in 1H-NMR of 13 and 14 spectra is easy to verify the 
complete formation of the complexes thanks to the appearance of the doublet of the 
pyridine ortho proton, that due to the coordination to platinum are shifted to lower fields 
(9-10 ppm depending on the complex and solvents). In the aromatic region, the singlet of 
the triazole ring proton at 8.33 ppm (for 13) or the doublet of NH at 8.01 ppm (for 14), 
together with the pattern and integration of the signals of glucose unit between 3.5 and 5.5 
ppm, gave other proofs of the effective coordination of the ancillary ligand. The presence 
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of the chelating ligand is confirmed by the presence of a triplet and a doublet related to the 
pyridine protons between 7.50 and 8.22 ppm.  
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Figure 4.8 Synthesis of the of the complexes 13 and 14. 
 
 
Figure 4.9 1H-NMR (hexafluoroisopropanhol-d2, 400 MHz) of the complex 13.  
a) 
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Figure 4.10 1H-NMR (CDCl3, 400 MHz) of the complex 14. 
 
Interestingly, the synthesis of complexes 13 and 14 could therefore been easily achieved 
despite the presence of several C=O groups and bulky carbohydrate unit on the ancillary 
ligand. 
The sugar moiety of the so obtained complexes were then deprotected using the usual 
Zemplen condition (fig. 4.11): the compounds 13 and 14 ware suspended in MeOH and a 
1M solution of sodium methoxide in MeOH was added dropwise until pH 9 was reached. 
The reaction is stirred from two up to four hours until complete deprotection was 
achieved as determined from TLC and ESI-MS. As in the previous case, the ESI-MS 
confirmed the presence of the deprotected complexes. In the 1H-NMR spectra the 
disappearance of the signals of the CH3 of the acetyl groups between 1.90 and 2.00 ppm 
confirm the complete deprotection of the compounds 13 and 14 (fig. 4.12 and 4.13 
respectively). 
The deprotection of the ancillary ligands before complexation with platinum was also 
tried, but in this case, the reaction does not lead to the desired compound. So, seeing that 
the complexes survive the deprotection reaction, we decided to carry out only the 
deprotection on the Pt complexes.  
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Figure 4.11 Deprotection of the complexes 13 and 14. 
 
 
Figure 4.12 1H-NMR (D2O/THF-d8 2/1, 400 MHz) of the complex 15.  
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Figure 4.13  1H-NMR (D2O/THF-d8 2/1, 400 MHz) of the complex 16.  
.  
 
4.2.3 Photophysics 
 
The photophysical data are listed in table 4.1 and the absorption and emission spectra 
displayed in figure 4.12 and 4.13. In diluted solution, the complexes exhibit strong 
absorption bands (ε = 3.0 – 1.0 × 104 M−1 cm−1 and ε = 2.0 – 0.1 × 104 M−1 cm−1 for 13 and 14, 
respectively) at high energy (λ < 350 nm). On the basis of closely related platinum 
complexes reported in literature,10 these bands mainly correspond to convolution of 
singlet-manifold ligand-centered (1LC) transitions involving the tridentate chromophoric 
ligand (̟ – ̟∗) with a minor contribution of metal-centered d orbitals. The low energy (λ  
= 350–500 nm), broader, featureless and less intense band (ε ≤ 103 M−1 cm−1) represents the 
S0 → S1 transition, and mainly involves the platinum d orbitals (partially mixed with the ̟ 
orbitals of the tridentate ligand) and ̟∗ orbitals of the chelate. This transition can be 
ascribed to the spin-allowed singlet-manifold metal-ligand-to-ligand charge-transfer 
(1MLLCT). Upon excitation at 300 nm, at room temperature, both complexes 13 and 14 
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showed structured emission at 464, 483 and 528 nm in hexafluoroisopropanol and 
chloroform, respectively, with a clear vibronic progression of 848-1765 cm-1, as shown in 
figure 4.13a for 13 and figure 4.13b for 14. Such finding suggests an emitting state with 
sizeable LC character.  In solution, in both degassed and air-equilibrated conditions, the 
compounds emit with rather low quantum yield (Φem = 3–4%) and the excited-state decays 
display relatively fast bi-exponential kinetics in the order of hundred of nanoseconds and 
few nanoseconds for the longer and shorter component, respectively, which are only 
slightly sensitive to dioxygen quenching. 
Going from room temperature to 77 K in CHCl3/MeOH 1/3 glassy matrix, for both 
complexes the emission spectra display a more pronounced vibronic structure and only a 
slight hypsochromic shift (see fig. 4.14), with a concomitant prolongation of the excited-
state lifetimes, that reach values as long as about 9 µs. All these findings are indicative of 
an emissive excited state with a mainly 3LC character and a weak 3MLCT nature. 
 
Complex 
λem rt 
[nm] 
λem 
77K 
[nm] 
Φem 
aer 
Φem 
degas 
τ (rt) aer [µs] 
τ (rt) degas 
[µs] 
τ (77K) [µs] 
13 
464, 
483, 
528 
454, 
484, 
521, 
~600sh 
0.03 0.04 
0,316 (93%)  
0,0028 (7%) 
0,433 
9,36 (54,4%)   
3,042 (45,6%) 
14 
464, 
483, 
528 
454, 
484, 
521, 
~560sh 
0.03 0.04 
0,405 (83,14%) 
0,004 (16,86%) 
0,515 (69,3%) 
0,005 (30,7%) 
9,39 (8,25%) 
0,009 
(91,75%) 
Table 4.1 Photophysical properties of complexes 13 and 14, “sh” denotes a shoulder. 
 
The studied compounds show similar properties to the Pt complexes present in 
literature.10 
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Figure 4.12 Absorption spectra (at concentration of 5*10-5 M) of 13 (hexafluoroisopropanol, left) and 14 
(CDCl3,right). 
 
 
Figure 4.13 Excitation (black lines) and emission (red broken lines) spectra (at concentration of 5*10-5 M) of 
13 (hexafluoroisopropanol, left) and 14 (CDCl3, right). The samples were excited at λexc = 300 nm. The 
excitation spectra were recorded at λem = 464 nm. 
 
 
Figure 4.13 Emission spectra (at concentration of 1*10-6 M) of 13 (hexafluoroisopropanol, left) and 14 
(CDCl3,right) at 77 K in CHCl3/MeOH 1/3 glassy matrix. The samples were excited at exc = 300 nm.. 
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The photophysical property of the deprotected compounds are now under study. 
 
 
4.3 Conclusion 
 
Four different luminescent N^N^N platinum complexes with a pyridine-based sugar 
functionalized ancillary ligand were synthesized using the same sugar (D-glucose) but 
different way to link the sugar to the pyridine ring and different distance between the 
sugar and the pyridine. Two complexes (13 and 14) present protected glucoside units and 
are soluble in organic solvents, and two others (15 and 16) present the deprotected 
glucoside moiety and are soluble in acqueous solvents. The different spacers were also 
chosen on the basis of easy and straightforward methods of conjugation and for their 
polarity that should also help the solubility in water of the deprotected compounds.  
The photophysical properties of these complexes were studied up to now only on the 
protected compounds but the photophysical behaviour of the deprotected complexes is 
under investigation. From the absorption spectra of 13 and 14 in diluted solution is 
possible to underline two different contributions, one stronger, involving the tridentate 
chromoforic lingand (1LC) and one less intense that can be ascribed to the spin-allowed 
singlet-manifold metal-ligand-to-ligand charge-transfer (1MLLCT). Both complexes 13 and 
14 showed structured emission with a clear vibronic progression, that suggests an emitting 
state with sizeable LC character.  In solution, in both degassed and air-equilibrated 
conditions, the compounds emit with rather low quantum yield (Φem = 3–4%). Going from 
room temperature to 77 K for both complexes the emission spectra display a more 
pronounced vibronic structure and only a slight hypsochromic shift, with a concomitant 
elongation of the excited-state lifetimes, that reach values as long as about 9 µs. All these 
findings are indicative of an emissive excited state with a mainly 3LC character and a weak 
3MLCT nature. 
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4.4 Experimental Part 
 
General Information. All moisture sensitive reactions were carried out under nitrogen 
atmosphere, using previously oven-dried glassware. Dry CHCl3 and dry DMF were 
prepared according to standard procedures, distilled before use and stored over 3 or 4 Å 
molecular sieves, respectively, while dry THF was obtained from commercial sources. 
Most of the solvents and reagents were obtained from commercial sources and used 
without further purification. Analytical TLCs were performed using prepared plates of 
silica gel (Merck 60 F-254 on aluminum) and then, according to the functional groups 
present on the molecules, revealed with UV light or using staining reagents: H2SO4 (5% in 
EtOH), basic solution of KMnO4 (0.75% in H2O). Merck silica gel 60 (70-230 mesh) was 
used for flash chromatography and for preparative TLC plates. 1H NMR spectra were 
recorded on Bruker AV300 and Bruker AV400 spectrometers (observation of 1H nucleus at 
300 MHz and 400 MHz respectively) and 19F NMR spectra on Bruker AV400 spectrometer 
(observation of 19F nucleus at 376 MHz). All chemical shifts are reported in part per 
million (ppm) using the residual peak of the deuterated solvent, whose values are referred 
to tetramethylsilane (TMS, δTMS = 0), as internal standard. Electrospray ionization (ESI) 
mass analyses were performed with a Waters spectrometer. Microwave reactions were 
performed using a CEM Discovery System reactor. Absorption spectra were measured on 
a Shimadzu UV-3600 spectrophotometer double-beam UV–VIS–NIR spectrometer and 
baseline corrected. Steady-state emission spectra were recorded on a Horiba Jobin−Yvon 
IBH FL-322 Fluorolog 3 spectrometer equipped with a 450 W xenon arc lamp, double-
grating excitation, and emission monochromators (2.1 nm mm−1 of dispersion; 1200 
grooves mm−1) and a TBX-4-X single photon-counting detector. Emission and excitation 
spectra were corrected for source intensity (lamp and grating) and emission spectral 
response (detector and grating) by standard correction curves. Solution state time-resolved 
measurements were performed using the time-correlated single-photon counting (TCSPC) 
option of a Picoquant FluoTime 300 (PicoQuant GmbH, Germany). A pulsed laser diode 
LDH-P-C-375 (l = 375 nm, pulse FWHM <70ps, repetition rate 200 kHz – 40 MHz) was 
used to excite the sample and mounted directly on the sample chamber at 90°. Data 
analysis was performed using the commercially available software (FluoFit, PicoQuant). 
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1,2,3,4,6-penta-O-acetyl-β-D-glucopyranoside 2 
In a two neck round bottom flask 6.32 g of sodium acetate (0.077 mol) were suspended in 
28 mL of acetic anhydride (0.27 mol) and heated to 130 °C. At this temperature D-glucose 
(2.0 g, 0.011 mol) was slowly added. The mixture was stirred at 130°C for 2 h and checked 
via TLC (eluent: AcOEt/hexane 1:1). When the reaction was complete it was poured into a 
flask containing 150 mL of ice and water (5 times the amount of acetic anhydride). The 
mixture was then stirred at room temperature overnight. The solid formed was recovered 
by filtration on a Buchner funnel. Product 2 was obtained as white solid in 65% yield. 1H 
NMR (300 MHz, CDCl3): δ (ppm) 5.71 (d, J = 8.1 Hz, 1H, H1), 5.25 (t, J = 9.3 Hz, 1H, H3), 
5.16 – 5.09 (m, 2H, H2, H4), 4.29 (dd, J = 4.5, 12.6 Hz, 1H, H6), 4.11 (dd, J = 2.1, 12.6 Hz, 1H, 
H6’), 3.86 – 3.80 (m, 1H, H5), 2.10, 2.08, 2.03, 2.01 (4s, 12H, CH3). The product shows the 
same physical-chemical properties reported in the literature. 2 
 
1-(2-Bromoethoxy)-2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 3 
In a two neck round bottom flask 1.0 g of 2 (2.56 mmol) were suspended in 20 mL of dry 
CH2Cl2 and cooled with ice bath to 0 °C. At this temperature were added first 
bromoethanol (0.24 mL, 3.48 mmol), then borontrifluoride etherate (1.20 mL, 10.2 mmol). 
The mixture was slowly heated at room temperature. The reaction is stirred for 24h and 
checked via TLC (eluent: hex/AcOEt 6:4). When the reaction was complete, it was 
quenched with a saturated solution of NaCl (20mL). The organic layer was extracted and 
the water phase washed with CH2Cl2 (3x20mL). The combined organic phases were dried 
on anhydrous Na2SO4, filtered and evaporated under reduced pressure. The crude was 
purified by flash chromatography (eluent: hex/AcOEt 6:4) giving the product 3 as 
yellowish solid in 60% yield. 1H NMR (300 MHz, CDCl3): δ (ppm) 5.20 (t, J = 11.7 Hz, 1H, 
H3), 5.09 – 4.96 (m, 2H, H2, H4), 4.55 (d, J = 7.8 Hz, 1H, H1), 4.24 (dd, J = 4.5, 12.3 Hz, 1H, 
H6), 4.15 – 4.10 (m, 2H, H6’, BrCH2aCH2), 3.83 – 3.76 (m, 1H, BrCH2bCH2), 3.72 – 3.66 (m, 
1H, H5), 3.46 – 3.41 (m, 2H, CH2CH2Br), 2.09, 2.05, 1.99, 1.98 (4s, 12H, CH3). The product 
shows the same physical-chemical properties reported in the literature. 3 
 
1-(2-Azidoethoxy)-2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 4 
In a two neck round bottom flask, 0.228 g of 3 (0.5 mmol) were suspended in 4 mL of dry 
DMF. Then sodium azide (0.097 g, 1.5 mmol) was added. The mixture was heated at 65 °C 
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and stirred for 24h, checked via TLC (eluent: hex/AcOEt 6:4). When the reaction was 
complete, it was quenched with water (5mL) and extracted with AcOEt (5mL). The water 
was washed with water (2x5mL). The combined organic phases were dried on anhydrous 
Na2SO4, filtered and evaporated under reduced pressure. The product 4 was obtained as 
white solid in 87% yield. 1H NMR (300 MHz, CDCl3): δ (ppm) 5.12 (t, J = 9.3 Hz, 1H, H3), 
5.02 – 4.88 (m, 2H, H4, H2), 4.52 (d, J = 7.8 Hz, 1H, H1), 4.16 (dd, J = 4.8, 12.4 Hz, 1H, H6), 
4.05 (dd, J = 2.7, 12.4 Hz, 1H, H6’), 3.97 – 3.90 (m, 1H, CH2aCH2), 3.72 – 3.66 (m, 1H, H5), 
3.46 – 3.41 (m, 2H, CH2aCH2Br) 3.67 – 3.57 (m, 2H, H5, CH2bCH2Br), 3.43 – 3.35 (m,1H, 
CH2CH2aBr), 2.23 – 3.16 (m, 1H, CH2CH2bBr), 1.98, 1.95, 1.93, 1.90 (4s, 12H, CH3). The 
product shows the same physical-chemical properties reported in the literature. 3 
 
4-(Trimethylsilylethynyl)pyridine 6 
A two neck round bottom flask containing Pd(PPh3)2Cl2 (0.03 g, 0.044 mmol), CuI (0.09 g, 
0.49 mmol) and 4-iodopyridine (1g, 4.9 mmol) was evacuated and filled with nitrogen 
three times. Then diisopropylamine (3.56 mL, 25.3 mmol) and THF (20 mL) were added 
via a syringe while stirring and the solution is bubbled 20 min. with N2. At this point 
trimethylsilylacetylene (1.38 mL, 9.76 mmol) was added. The dark brown mixture was 
stirred for 18 h at room temperature. Reaction mixture was poured into water and 
extracted with CH2Cl2 (20mL×3). The collected organic layers were dried with MgSO4 and 
filtered. Solvent was removed via rotary evaporation. The product was isolated by column 
chromatography (eluent: cyclohexane/AcOEt 1/1) which afforded 6 as a dark oil in 87 % 
yield. 1H NMR (400 MHz, CDCl3) δ (ppm) 8.62 (bs, 2 H, pyridine CH), 7.33 (bs, 2 H, 
pyridine CH), 0.26 (s, 9 H, SiCH3). The product shows the same physical-chemical 
properties reported in the literature. 4 
 
4-Ethynylpyridine 7 
Compound 6 (0.719 g, 4.10 mmol) was dissolved in MeOH (10 mL) and CH2Cl2 (5 mL) in a 
round bottom flask. Anhydrous KOH (0.460 g, 8.20 mmol) was added to the mixture 
which was then stirred for 3 h. The reaction was partitioned between CH2Cl2 and water, 
and the aqueous layer was further extracted two times (2x15 mL CH2Cl2). The combined 
organic solution was then dried with anhydrous MgSO4, and the solvent was removed by 
rotary evaporation which afforded 7 as an off-white solid in 50% yield. 1H NMR (400 
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MHz, CDCl3) δ (ppm) 8.60 (dd, J = 1.5, 4.4 Hz, 2 H, pyridine CH), 7.35 (dd, J = 1.5, 4.4 Hz, 2 
H, pyridine CH), 3.30 (s, 1 H, CCH). The product shows the same physical-chemical 
properties reported in the literature. 4 
 
2-(Acetoxymethyl)-6-(2-(4-(pyridin-4-yl)-1H-1,2,3-triazol-1-yl)ethoxy)tetrahydro-2H-
pyran-3,4,5-triyl triacetate 8 
In a microwave tube 4 (60 mg, 0.150 mmol), 7 (10 mg, 0.097 mmol), CuSO4 (7 mg, 0.029 
mmol) and sodium ascorbate (11mg, 0.058 mmol) were dissolved in 1mL of DMF and 5 
drops of water. The reaction was heated at 80 °C by microwave irradiation (150W) for 20 
min. When the reaction was complete (checked with TLC eluent CH2Cl2/MeOH 95/5) the 
mixture is poured into water and extracted with CH2Cl2 (2x2mL). The combined organic 
layer were dried on anhydrous MgSO4, filtered and the solvent is removed under reduced 
pressure. The crude was purified via column cromatography (eluent CH2Cl2/MeOH 9/1) 
giving the pure product as a yellowish oil in 75% yield. 1H-NMR (400 MHz, CDCl3): δ 
(ppm) 8.79 (bs, 2H, pyridine CH), 8.20 (s, 1H, triazole CH), 7.84 (bs, 2H, pyridine CH), 5.15 
(t, 1H, J = 9.52 Hz, H3), 5.06 – 5.97 (m, 2H, H4, H2), 4.70 – 4.66 (m, 1H, H8), 4.58 – 4.52 (m, 
1H, H8’), 4.44 (d, 1H, J = 7.8 Hz, H1), 4.26 – 4.20 (m, 2H, H6, H7), 4.11 – 4.07 (m, 1H, H6’), 
3.91 – 3.85 (m, 1H, H7’), 3.69 – 3.65 (m, 1H, H5), 2.03, 1.97, 1.93, 1.71 (4s, 12H, CH3). 13C-
NMR (100 MHz, CDCl3): δ (ppm) 170.5, 170.1, 169.7, 169.4 (CO), 144.7 (triazole C), 143.3 
(pyridine C), 125.4 (triazole CH), 121.4, 121.3 (pyridine CH), 100.3 (C1), 72.1 (C3, C5), 71.1 
(C2), 68.2 (C4), 67.0 (OCH2), 61.7 (C6), 50.5 (NCH2), 20.7, 20.5 (CH3). ESI-MS: m/z 521.19 
(M+H)+, 543.17 (M+Na)+. 
 
Complex 13 
In a two neck round bottom flask PtCl2DMSO2 (105 mg, 0.25 mmol) and CF3 ligand (86 
mg, 0.25 mmol) was dissolved in CHCl3 (11.3 mL) and DIPEA (104µL, 0.59 mmol) under 
N2. The solution was stirred for 20 min. Compound 8 (150mg, 0.30 mmol) was added and 
the solution was heated at 60 °C overnight. When the reaction was complete (checked with 
TLC eluent AcOEt/Acetone 8/2) the solvent is removed by rotary evaporation. The 
compound was purified by precipitation from CH2Cl2. 1H-NMR (400MHz, hexafluoro 
isopropanol-d2): δ (ppm) 8.99 (d, 2H, J = 6.8 Hz, pyridine CH), 8.33 (s, 1H, triazole H), 8.22 
(t, 1H, J = 8 Hz, ligand CH), 8.05 – 8.01 (m, 4H, ligand and pyridine CH), 5.32 (t, 1H, J = 9.4 
Chapter 4 
113 
Hz, H3), 5.16 (t, 1H, J = 9.4 Hz, H4), 5.06 (t, 1H, J = 8 Hz, H2), 4.63 (d, 1H, J = 8 Hz, H1), 
4.42 – 4.28 (under the solvent peak, 4H, CH2), 4.21 – 4.17 (m, 1H, H6), 4.05 – 3.99 (m, 1H, 
H6’), 3.82 – 3.79 (m, 1H, H5), 2.13, 2.07, 2.04, 1.91 (4s, 12H, CH3). 19F-NMR (376 MHz, 
hexafluoro isopropanol-d2): δ (ppm) -60.82 (CF3). ESI-MS: m/z 1063.17 (M+Na)+. 
 
1-Azido-2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 10  
In a round bottom flask α-bromoglucose (1g, 2.52 mmol),NaN3 (0.33 g, 5.03 mmol) and 
tetrabutylammonium hydrogen sulfate (0.85 g, 2.52 mmol) were dissolved in CH2Cl2 
(10mL). A saturated solution of NaHCO3 (10mL) is added and the solution is vigorously 
stirred for 2 hr. The reaction is monitored with TLC (eluent AcOEt/CH2Cl2 1/1). The 
mixture was poured in AcOEt (4 times the volume of CH2Cl2) and extracted. The organic 
layer is washed with water, a saturated solution of NaHCO3 and brine, then dried on 
anhydrous MgSO4. The solvent was removed by rotary evaporation giving 10 in 91% 
yield. 1H-NMR (400 MHz, CDCl3): δ (ppm) 5.19 (t, 1H, J = 9.6 Hz, H3), 5.07 (t, 1H, J = 6 Hz, 
H4), 4.91 (t, 1H, J = 9.2 Hz, H2), 4.64 (d, 1H, J = 9.2 Hz, H1), 4.24 (dd, 1H, J1 = 4.8 Hz, 12.4 
Hz, H6), 4.15 – 4.05 (m, 1H, H6’), 3.80 – 3.77 (m, 1H, H5), 2.06, 2.05, 2.00, 1.97 (4s, 12H, 
CH3). The product shows the same physical-chemical properties reported in the literature. 
11 
 
1-Amino-2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 11 
In a Parr reactor, compound 10 (1.7 g, 4.55 mmol) was dissolved in CH3CN (60ml) and 
Pd/C (catalytic amount) was added. The reaction was stirred at room temperature 
overnight (H2 pressure = 2bar). When the reaction was complete (checked with TLC, 
eluent CH2Cl2/MeOH 9/1) the catalyst was filtered off and the solvent was removed by 
rotary evaporation. The product 11 was obtained as a white solid in a 90% yield. 1H-NMR 
(400 MHz, CDCl3): δ (ppm) 5.27 (t, 1H, J = 9.6 Hz, H3), 5.06 (t, 1H, J = 9.6 Hz, H4), 4.85 (t, 
1H, J = 9.6 Hz, H2), 4.27 – 4.21 (m, 2H, H2, H6), 4.13 (dd, 1H, J = 2.4, 12.4, H6’), 3.74 – 3.69 
(m, 1H, H5), 2.12, 2.09, 2.05, 2.03 (4s, 12H, CH3). The product shows the same physical-
chemical properties reported in the literature. 12 
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N-(2,3,4,6-tetra-O-acetyl-β- D -Glucopyranosyl)-pyridine-4-carboxamide 12 
In a round bottom flask isonicotinic acid (50 mg, 0.4 mmol), EDC (78 mg, 0.4 mmol) and 
DMAP (50 mg, 0.4 mmol) were dissolved in dry THF (5mL) and the reaction is stirred at 0 
°C for 5 min. Then the sugar 11 was added and the mixture was stirred ad room 
temperature overnight. The reaction was checked with TLC (eluent AcOEt). When the 
reaction was complete was poured into AcOEt and washed with water (5mL) and brine 
(5mL). The organic phase is dried over anhydrous Na2SO4 and the solvent was removed 
via rotary evaporation. The crude was purified via column chromathography giving the 
product as a white solid in 50% yield. 1H-NMR (400 MHz, CDCl3): 8.75 (d, 2H, J = 5.6 Hz, 
pyridine CH), 7.60 (d, 2H, J = 5.6 Hz, pyridine CH), 7.55 (d, 1H, J = 6.6 Hz, NH), 5.45 – 5.36 
(m, 2H, H3, H1), 5.11 – 5.00 (m, 2H, H4, H2), 4.32 (dd, 1H, J = 4.4, 14.2Hz, H6), 4.13 – 4.08 
(m, 1H, H6’), 3.93 – 3.89 (m, 1H, H5), 2.06, 2.05, 2.04, 2.03 (4s, 12H, CH3). The product 
shows the same physical-chemical properties reported in the literature. 9 
 
Complex 14 
In a two neck round bottom flask PtCl2DMSO2 (46 mg, 0.1 mmol) and CF3 ligand (38 mg, 
0.1 mmol) was dissolved in CHCl3 (7 mL) and K2HPO4 (57 mg, 0.33 mmol) under N2. The 
solution was stirred for 20 min. Compound 12 (59mg, 0.13 mmol) was added and the 
solution was stirred ad room temperature overnight. When the reaction was complete 
(checked with TLC eluent AcOEt/Acetone 8/2) the mixture is diluted into CHCl3 and 
extracted with water. The solvent is removed by rotary evaporation. 1H-NMR (400MHz, 
CDCl3): δ (ppm) 9.50 (d, 2H, J = 5.6 Hz, pyridine CH), 8.01 (d, 1H, J = 8.0 Hz, NH), 7.94 (t, 
1H, J = 8.0 Hz, ligand CH), 7.66 (d, 2H, J = 5.6 Hz, pyridine CH), 7.56 (d , 2H, J = 8 Hz, 
ligand CH), 5.58 (t, 1H. J = 8.8 Hz, H3), 5.49 (t, 1H, J = 9.2 Hz, H4), 5.21 (m, 2H, H2, H1), 
4.42 (dd, 1H, J = 4.4, 12.8 Hz), 4.24 (d, 1H, J = 12.8 Hz, H6’), 4.08 – 4.05 (m, 1H, H5), 2.20, 
2.14, 2.11, 2.08 (4s, 12H, CH3). 19F-NMR (376 MHz, CDCl3): δ (ppm) 61,03 (CF3) ESI-MS: 
m/z 1017.15 (M+Na)+. 
 
Complex 15 
In a round bottom flask, complex 13 (80mg, 0.075) was suspended in MeOH and a solution 
1M of MeONa was added dropwise until pH 9. The reaction was stirred ad room 
temperature for four hours and checked with TLC (eluent AcOEt/acetone 8/2). The 
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reaction was centrifuged and the solid was dried under vacuum. 1H-NMR (400 MHz, 
D2O/THF-d8 = 2/1): δ (ppm) 8.78 (bs, 2H, pyridine CH), 8.54 (bs, 1H, triazole CH), 7.92 
(bs, 1H, ligand CH), 7.32 (bs, 2H, pyridine CH), 7.24 (bs, 2H, ligand CH), 4.52 (d, 1H, J = 8 
Hz, H1), 4.35 – 4.33 (m, 2H, CH2), 4.19 – 4.16 (m, 2H, CH2), 3.93 – 3.87 (m, 1H, H4), 3.72 – 
3.68 (under solvent peak, H3), 3.51 – 3.46 (m, 2H, H5, H6’) 3.36 – 3.26 (m, 2H, H2 H6). ESI-
MS: m/z 895 (M+H)+, 917 (M+Na)+. 
 
Complex 16 
In a round bottom flask, compound 14 (15mg, 0.015) was suspended in MeOH and a 
solution 1M of MeONa was added drop by drop until pH 9. The reaction was stirred ad 
room temperature for two hours and checked with TLC (eluent AcOEt). The reaction was 
centrifuged and the solid was dried under vacuum. 1H-NMR (400 MHz, D2O/THF-d8 = 
2/1):  δ (ppm) 9.10 (d, 2H, J = 5.6 Hz, pyridine CH), 8.12 (t, 1H, J = 8 Hz, ligand CH), 7.69 
(d, 2H, J = 5.6 Hz, pyridine CH), 7.45 (d, 2H, J = 8 Hz, ligand CH), 6.92 (NH), 5.24 (d, 1H, J 
= 8.4 Hz, H1), 3.92 – 3.91 (m, 1H, H4), 3.81– 3.80 (m, 1H, H3), 3.71 -3.69 (under solvent 
peak, m, 2H, H5, H6), 3.64 – 3.63 (m, 1H, H2), 3.55 – 3.53 (m, 1H, H6’) . ESI-MS: m/z 849 
(M+Na)+. 
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